JP2023510108A - Ｄｇｋ阻害剤およびチェックポイントアンタゴニストの組み合わせ - Google Patents

Ｄｇｋ阻害剤およびチェックポイントアンタゴニストの組み合わせ Download PDF

Info

Publication number: JP2023510108A
Authority: JP; Japan
Prior art keywords: alkyl; substituted; cycloalkyl; dgkα; dgkζ
Prior art date: 2019-12-19
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

JP2022537676A

Other languages

English (en)

Japanese (ja)

Other versions

JPWO2021127554A5 (fr

Inventor

ウィー，スーザン

エルベンチ，ジョセフ

ワン，シンユー

ベラパルチ，アッペンダー

エスチュパック，ルイス

ピーダルネ，チェタン

ディン，ミン

ジージェントルズ，ロバート

フアン，ヤジョン

ダブリューマーティン，スコット

エムマクドナルド，アイバー

イーオルソン，リチャード

ジェン，シャオファン

エストカルスキー，ジョン

ダスグプタ，ビレシュワル

ナラヤナラオカンブレ，マンジュナタ

マヌーリ，ラジュ

ラーマン，ハシブル

ラオジャラガム，プラサダ

ロイ，ソーミャ

トヌクヌル，ゴピキシャン

ヴェライアー，シヴァスダル

サンカラウォリアー，ジャヤクマール

ラトナカルレディ，コタ

ラジャ，ティルベンカダム

グリューネンフェルダー，デニース

ジェイウィクロスキー，マイケル

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Bristol Myers Squibb Co

Original Assignee

Bristol Myers Squibb Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2019-12-19

Filing date

2020-12-18

Publication date

2023-03-13

2020-12-18 Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co

2023-03-13 Publication of JP2023510108A publication Critical patent/JP2023510108A/ja

2023-12-25 Publication of JPWO2021127554A5 publication Critical patent/JPWO2021127554A5/ja

Status Pending legal-status Critical Current

Links

239000005557 antagonist Substances 0.000 title claims abstract description 118
239000003112 inhibitor Substances 0.000 title claims abstract description 101
108010062677 Diacylglycerol Kinase Proteins 0.000 title claims abstract description 42
108010058222 Deoxyguanosine kinase Proteins 0.000 title claims 6
102100022732 Diacylglycerol kinase beta Human genes 0.000 title claims 6
238000000034 method Methods 0.000 claims abstract description 158
206010028980 Neoplasm Diseases 0.000 claims abstract description 153
108010074708 B7-H1 Antigen Proteins 0.000 claims abstract description 63
101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims abstract description 56
201000011510 cancer Diseases 0.000 claims abstract description 55
102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims abstract description 35
210000000987 immune system Anatomy 0.000 claims abstract description 18
230000000638 stimulation Effects 0.000 claims abstract description 5
150000001875 compounds Chemical class 0.000 claims description 192
-1 cyanocyclopropyl Chemical group 0.000 claims description 126
125000000217 alkyl group Chemical group 0.000 claims description 117
229910052731 fluorine Inorganic materials 0.000 claims description 85
229910052801 chlorine Inorganic materials 0.000 claims description 83
101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 claims description 77
102100040678 Programmed cell death protein 1 Human genes 0.000 claims description 76
102000008096 B7-H1 Antigen Human genes 0.000 claims description 62
229940045513 CTLA4 antagonist Drugs 0.000 claims description 61
210000001744 T-lymphocyte Anatomy 0.000 claims description 61
150000003839 salts Chemical class 0.000 claims description 59
125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 58
125000006645 (C3-C4) cycloalkyl group Chemical group 0.000 claims description 52
125000004428 fluoroalkoxy group Chemical group 0.000 claims description 50
125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 49
239000000427 antigen Substances 0.000 claims description 46
125000004122 cyclic group Chemical group 0.000 claims description 46
108091007433 antigens Proteins 0.000 claims description 45
102000036639 antigens Human genes 0.000 claims description 45
125000001424 substituent group Chemical group 0.000 claims description 44
229910052794 bromium Inorganic materials 0.000 claims description 43
125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 41
238000011282 treatment Methods 0.000 claims description 41
125000000623 heterocyclic group Chemical group 0.000 claims description 40
125000003709 fluoroalkyl group Chemical group 0.000 claims description 39
229910052739 hydrogen Inorganic materials 0.000 claims description 34
229910052799 carbon Inorganic materials 0.000 claims description 31
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 31
125000006274 (C1-C3)alkoxy group Chemical group 0.000 claims description 30
230000002829 reductive effect Effects 0.000 claims description 27
229960005386 ipilimumab Drugs 0.000 claims description 25
238000010171 animal model Methods 0.000 claims description 23
102000048362 human PDCD1 Human genes 0.000 claims description 23
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 23
125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 20
125000002757 morpholinyl group Chemical group 0.000 claims description 20
101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 claims description 19
125000003545 alkoxy group Chemical group 0.000 claims description 19
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 19
102000048776 human CD274 Human genes 0.000 claims description 19
229960003301 nivolumab Drugs 0.000 claims description 18
125000004432 carbon atom Chemical group C* 0.000 claims description 17
229960003852 atezolizumab Drugs 0.000 claims description 16
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 16
125000002853 C1-C4 hydroxyalkyl group Chemical group 0.000 claims description 13
230000000259 anti-tumor effect Effects 0.000 claims description 12
125000001412 tetrahydropyranyl group Chemical group 0.000 claims description 12
125000003342 alkenyl group Chemical group 0.000 claims description 10
125000000304 alkynyl group Chemical group 0.000 claims description 10
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 10
230000002476 tumorcidal effect Effects 0.000 claims description 10
239000012636 effector Substances 0.000 claims description 9
210000000822 natural killer cell Anatomy 0.000 claims description 9
125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims description 8
125000001072 heteroaryl group Chemical group 0.000 claims description 8
125000001715 oxadiazolyl group Chemical group 0.000 claims description 8
229960002621 pembrolizumab Drugs 0.000 claims description 8
125000004076 pyridyl group Chemical group 0.000 claims description 8
125000001544 thienyl group Chemical group 0.000 claims description 8
125000001425 triazolyl group Chemical group 0.000 claims description 8
239000003795 chemical substances by application Substances 0.000 claims description 7
125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 6
125000004966 cyanoalkyl group Chemical group 0.000 claims description 6
125000000753 cycloalkyl group Chemical group 0.000 claims description 6
239000007788 liquid Substances 0.000 claims description 6
125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 claims description 6
101001044817 Homo sapiens Diacylglycerol kinase alpha Proteins 0.000 claims description 5
101000864576 Homo sapiens Diacylglycerol kinase zeta Proteins 0.000 claims description 5
229940124060 PD-1 antagonist Drugs 0.000 claims description 5
230000003213 activating effect Effects 0.000 claims description 5
125000002768 hydroxyalkyl group Chemical group 0.000 claims description 5
229940076838 Immune checkpoint inhibitor Drugs 0.000 claims description 4
230000004913 activation Effects 0.000 claims description 4
229960000074 biopharmaceutical Drugs 0.000 claims description 4
230000005754 cellular signaling Effects 0.000 claims description 4
125000005159 cyanoalkoxy group Chemical group 0.000 claims description 4
125000005879 dioxolanyl group Chemical group 0.000 claims description 4
239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims description 4
125000006431 methyl cyclopropyl group Chemical group 0.000 claims description 4
125000002950 monocyclic group Chemical group 0.000 claims description 4
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 4
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 4
125000003566 oxetanyl group Chemical group 0.000 claims description 4
125000003386 piperidinyl group Chemical group 0.000 claims description 4
125000000335 thiazolyl group Chemical group 0.000 claims description 4
229940123751 PD-L1 antagonist Drugs 0.000 claims description 3
210000004970 cd4 cell Anatomy 0.000 claims description 3
230000002441 reversible effect Effects 0.000 claims description 3
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 3
125000003118 aryl group Chemical group 0.000 claims description 2
238000002512 chemotherapy Methods 0.000 claims description 2
125000005348 fluorocycloalkyl group Chemical group 0.000 claims description 2
230000002489 hematologic effect Effects 0.000 claims description 2
231100001231 less toxic Toxicity 0.000 claims description 2
210000004986 primary T-cell Anatomy 0.000 claims description 2
238000001959 radiotherapy Methods 0.000 claims description 2
230000011664 signaling Effects 0.000 claims description 2
238000001356 surgical procedure Methods 0.000 claims description 2
230000007423 decrease Effects 0.000 claims 1
238000011275 oncology therapy Methods 0.000 claims 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 60
201000010099 disease Diseases 0.000 abstract description 45
102000011107 Diacylglycerol Kinase Human genes 0.000 abstract description 36
230000008901 benefit Effects 0.000 abstract description 12
208000035473 Communicable disease Diseases 0.000 abstract description 8
102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 abstract 1
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 375
239000012071 phase Substances 0.000 description 116
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 109
210000004027 cell Anatomy 0.000 description 104
229910001868 water Inorganic materials 0.000 description 96
101150044506 Dgki gene Proteins 0.000 description 92
238000004895 liquid chromatography mass spectrometry Methods 0.000 description 80
235000002639 sodium chloride Nutrition 0.000 description 64
239000000203 mixture Substances 0.000 description 58
USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 52
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 52
125000004093 cyano group Chemical group *C#N 0.000 description 51
239000005695 Ammonium acetate Substances 0.000 description 46
235000019257 ammonium acetate Nutrition 0.000 description 46
229940043376 ammonium acetate Drugs 0.000 description 46
238000006243 chemical reaction Methods 0.000 description 37
239000000243 solution Substances 0.000 description 35
230000005764 inhibitory process Effects 0.000 description 34
239000002904 solvent Substances 0.000 description 33
VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 32
239000000047 product Substances 0.000 description 31
238000003556 assay Methods 0.000 description 30
238000010828 elution Methods 0.000 description 29
JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-diisopropylethylamine Substances CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 28
239000007924 injection Substances 0.000 description 28
238000002347 injection Methods 0.000 description 28
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical class CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 27
241000699670 Mus sp. Species 0.000 description 27
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 27
239000011541 reaction mixture Substances 0.000 description 26
239000002245 particle Substances 0.000 description 25
102000008203 CTLA-4 Antigen Human genes 0.000 description 23
108010021064 CTLA-4 Antigen Proteins 0.000 description 22
101710089372 Programmed cell death protein 1 Proteins 0.000 description 22
230000000694 effects Effects 0.000 description 22
238000005481 NMR spectroscopy Methods 0.000 description 21
238000001514 detection method Methods 0.000 description 20
102000043321 human CTLA4 Human genes 0.000 description 20
239000003814 drug Substances 0.000 description 18
235000019439 ethyl acetate Nutrition 0.000 description 18
241001465754 Metazoa Species 0.000 description 17
238000002513 implantation Methods 0.000 description 17
229950009791 durvalumab Drugs 0.000 description 16
239000000725 suspension Substances 0.000 description 16
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 15
229950002916 avelumab Drugs 0.000 description 15
230000037396 body weight Effects 0.000 description 15
208000035475 disorder Diseases 0.000 description 15
238000012360 testing method Methods 0.000 description 15
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 14
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 14
239000012091 fetal bovine serum Substances 0.000 description 14
150000002632 lipids Chemical class 0.000 description 14
108090000765 processed proteins & peptides Proteins 0.000 description 14
239000003643 water by type Substances 0.000 description 14
108010074328 Interferon-gamma Proteins 0.000 description 13
239000003153 chemical reaction reagent Substances 0.000 description 13
239000003921 oil Substances 0.000 description 13
235000019198 oils Nutrition 0.000 description 13
239000008194 pharmaceutical composition Substances 0.000 description 13
230000003389 potentiating effect Effects 0.000 description 13
238000002953 preparative HPLC Methods 0.000 description 13
239000007787 solid Substances 0.000 description 13
210000004881 tumor cell Anatomy 0.000 description 13
239000003981 vehicle Substances 0.000 description 13
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
230000014759 maintenance of location Effects 0.000 description 12
239000002609 medium Substances 0.000 description 12
FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 12
238000010189 synthetic method Methods 0.000 description 12
102100037850 Interferon gamma Human genes 0.000 description 11
108010002350 Interleukin-2 Proteins 0.000 description 11
102000000588 Interleukin-2 Human genes 0.000 description 11
206010025323 Lymphomas Diseases 0.000 description 11
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 11
239000013058 crude material Substances 0.000 description 11
210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 11
230000001965 increasing effect Effects 0.000 description 11
239000000543 intermediate Substances 0.000 description 11
238000004519 manufacturing process Methods 0.000 description 11
239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 10
102000004190 Enzymes Human genes 0.000 description 10
108090000790 Enzymes Proteins 0.000 description 10
239000012981 Hank's balanced salt solution Substances 0.000 description 10
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical class OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 10
241000699666 Mus <mouse, genus> Species 0.000 description 10
102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 10
239000002671 adjuvant Substances 0.000 description 10
238000004458 analytical method Methods 0.000 description 10
239000007928 intraperitoneal injection Substances 0.000 description 10
230000004936 stimulating effect Effects 0.000 description 10
239000000872 buffer Substances 0.000 description 9
239000012043 crude product Substances 0.000 description 9
238000009472 formulation Methods 0.000 description 9
238000004128 high performance liquid chromatography Methods 0.000 description 9
230000002401 inhibitory effect Effects 0.000 description 9
238000007799 mixed lymphocyte reaction assay Methods 0.000 description 9
239000012044 organic layer Substances 0.000 description 9
238000002360 preparation method Methods 0.000 description 9
239000006228 supernatant Substances 0.000 description 9
239000003826 tablet Substances 0.000 description 9
238000002560 therapeutic procedure Methods 0.000 description 9
ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 8
108091003079 Bovine Serum Albumin Proteins 0.000 description 8
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 8
WREOTYWODABZMH-DTZQCDIJSA-N [[(2r,3s,4r,5r)-3,4-dihydroxy-5-[2-oxo-4-(2-phenylethoxyamino)pyrimidin-1-yl]oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]1N(C=C\1)C(=O)NC/1=N\OCCC1=CC=CC=C1 WREOTYWODABZMH-DTZQCDIJSA-N 0.000 description 8
150000001413 amino acids Chemical group 0.000 description 8
229940125758 compound 15 Drugs 0.000 description 8
229940126142 compound 16 Drugs 0.000 description 8
239000003995 emulsifying agent Substances 0.000 description 8
230000006870 function Effects 0.000 description 8
230000028993 immune response Effects 0.000 description 8
208000015181 infectious disease Diseases 0.000 description 8
239000002502 liposome Substances 0.000 description 8
239000012453 solvate Substances 0.000 description 8
229950007217 tremelimumab Drugs 0.000 description 8
230000003442 weekly effect Effects 0.000 description 8
241000282412 Homo Species 0.000 description 7
241000700605 Viruses Species 0.000 description 7
238000002648 combination therapy Methods 0.000 description 7
239000003599 detergent Substances 0.000 description 7
235000014113 dietary fatty acids Nutrition 0.000 description 7
229940079593 drug Drugs 0.000 description 7
239000000194 fatty acid Substances 0.000 description 7
229930195729 fatty acid Natural products 0.000 description 7
150000004665 fatty acids Chemical class 0.000 description 7
238000011534 incubation Methods 0.000 description 7
201000001441 melanoma Diseases 0.000 description 7
239000000693 micelle Substances 0.000 description 7
229910052757 nitrogen Inorganic materials 0.000 description 7
230000036961 partial effect Effects 0.000 description 7
239000003755 preservative agent Substances 0.000 description 7
102000004169 proteins and genes Human genes 0.000 description 7
108090000623 proteins and genes Proteins 0.000 description 7
239000011780 sodium chloride Substances 0.000 description 7
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
238000012815 AlphaLISA Methods 0.000 description 6
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
229920000858 Cyclodextrin Polymers 0.000 description 6
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 6
101100519207 Mus musculus Pdcd1 gene Proteins 0.000 description 6
206010035226 Plasma cell myeloma Diseases 0.000 description 6
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 6
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
239000004480 active ingredient Substances 0.000 description 6
210000004369 blood Anatomy 0.000 description 6
239000008280 blood Substances 0.000 description 6
239000012267 brine Substances 0.000 description 6
229910002091 carbon monoxide Inorganic materials 0.000 description 6
208000029742 colonic neoplasm Diseases 0.000 description 6
235000019441 ethanol Nutrition 0.000 description 6
239000000796 flavoring agent Substances 0.000 description 6
235000013355 food flavoring agent Nutrition 0.000 description 6
235000003599 food sweetener Nutrition 0.000 description 6
239000012634 fragment Substances 0.000 description 6
230000006054 immunological memory Effects 0.000 description 6
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 6
239000000126 substance Substances 0.000 description 6
239000003765 sweetening agent Substances 0.000 description 6
238000003786 synthesis reaction Methods 0.000 description 6
230000009258 tissue cross reactivity Effects 0.000 description 6
239000000080 wetting agent Substances 0.000 description 6
BORFCTSBIOZUFN-MNOVXSKESA-N 8-[(2S,5R)-2,5-dimethylpiperazin-1-yl]-5-methyl-6-oxo-1,5-naphthyridine-2-carbonitrile Chemical compound C[C@@H]1N(C[C@H](NC1)C)C1=CC(N(C=2C=CC(=NC1=2)C#N)C)=O BORFCTSBIOZUFN-MNOVXSKESA-N 0.000 description 5
102100027314 Beta-2-microglobulin Human genes 0.000 description 5
206010009944 Colon cancer Diseases 0.000 description 5
208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 5
229910019142 PO4 Inorganic materials 0.000 description 5
229920002565 Polyethylene Glycol 400 Polymers 0.000 description 5
208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 5
239000012980 RPMI-1640 medium Substances 0.000 description 5
AOBORMOPSGHCAX-UHFFFAOYSA-N Tocophersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-UHFFFAOYSA-N 0.000 description 5
208000036142 Viral infection Diseases 0.000 description 5
239000002253 acid Substances 0.000 description 5
229940124691 antibody therapeutics Drugs 0.000 description 5
239000007900 aqueous suspension Substances 0.000 description 5
239000002775 capsule Substances 0.000 description 5
210000004443 dendritic cell Anatomy 0.000 description 5
239000003085 diluting agent Substances 0.000 description 5
239000003937 drug carrier Substances 0.000 description 5
239000000839 emulsion Substances 0.000 description 5
230000002255 enzymatic effect Effects 0.000 description 5
150000002148 esters Chemical class 0.000 description 5
208000032839 leukemia Diseases 0.000 description 5
239000000463 material Substances 0.000 description 5
238000002156 mixing Methods 0.000 description 5
208000002154 non-small cell lung carcinoma Diseases 0.000 description 5
231100000252 nontoxic Toxicity 0.000 description 5
230000003000 nontoxic effect Effects 0.000 description 5
JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 5
235000021317 phosphate Nutrition 0.000 description 5
239000000843 powder Substances 0.000 description 5
230000002062 proliferating effect Effects 0.000 description 5
108020003175 receptors Proteins 0.000 description 5
102000005962 receptors Human genes 0.000 description 5
229910052938 sodium sulfate Inorganic materials 0.000 description 5
235000011152 sodium sulphate Nutrition 0.000 description 5
239000000758 substrate Substances 0.000 description 5
230000001629 suppression Effects 0.000 description 5
208000024891 symptom Diseases 0.000 description 5
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 5
210000001519 tissue Anatomy 0.000 description 5
230000004614 tumor growth Effects 0.000 description 5
208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 5
230000009385 viral infection Effects 0.000 description 5
PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 4
238000005160 1H NMR spectroscopy Methods 0.000 description 4
QBTXPCPOQVQZOB-ZWKOTPCHSA-N 4-[(2R,5S)-4-[bis(4-fluorophenyl)methyl]-2,5-dimethylpiperazin-1-yl]-6-bromo-1-methyl-2-oxo-1,5-naphthyridine-3-carbonitrile Chemical compound FC1=CC=C(C=C1)C(N1C[C@H](N(C[C@@H]1C)C1=C(C(N(C2=CC=C(N=C12)Br)C)=O)C#N)C)C1=CC=C(C=C1)F QBTXPCPOQVQZOB-ZWKOTPCHSA-N 0.000 description 4
BRELKQOMMUCNLU-XWZNDSGVSA-N 8-[(2S,5R)-4-[(4-fluorophenyl)-phenylmethyl]-2,5-dimethylpiperazin-1-yl]-5-methyl-6-oxo-1,5-naphthyridine-2-carbonitrile Chemical compound FC1=CC=C(C=C1)C(N1C[C@@H](N(C[C@H]1C)C1=CC(N(C=2C=CC(=NC1=2)C#N)C)=O)C)C1=CC=CC=C1 BRELKQOMMUCNLU-XWZNDSGVSA-N 0.000 description 4
OOIWSXYERVFIRZ-GOSISDBHSA-N 8-[(3R)-4-[bis(4-fluorophenyl)methyl]-3-methylpiperazin-1-yl]-5-methyl-6-oxo-1,5-naphthyridine-2,7-dicarbonitrile Chemical compound FC1=CC=C(C=C1)C(N1[C@@H](CN(CC1)C1=C(C(N(C=2C=CC(=NC1=2)C#N)C)=O)C#N)C)C1=CC=C(C=C1)F OOIWSXYERVFIRZ-GOSISDBHSA-N 0.000 description 4
XAHMIJCNFUSTMT-UHFFFAOYSA-N 8-[4-[bis(4-fluorophenyl)methyl]piperazin-1-yl]-5-methyl-7-nitro-6-oxo-1,5-naphthyridine-2-carbonitrile Chemical compound FC1=CC=C(C=C1)C(N1CCN(CC1)C1=C(C(N(C=2C=CC(=NC1=2)C#N)C)=O)[N+](=O)[O-])C1=CC=C(C=C1)F XAHMIJCNFUSTMT-UHFFFAOYSA-N 0.000 description 4
241000392139 Astarte Species 0.000 description 4
239000012275 CTLA-4 inhibitor Substances 0.000 description 4
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
239000004215 Carbon black (E152) Substances 0.000 description 4
101000609767 Dromaius novaehollandiae Ovalbumin Proteins 0.000 description 4
238000012286 ELISA Assay Methods 0.000 description 4
206010014733 Endometrial cancer Diseases 0.000 description 4
206010014759 Endometrial neoplasm Diseases 0.000 description 4
IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 4
101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 4
208000008839 Kidney Neoplasms Diseases 0.000 description 4
208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 4
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 description 4
108010047620 Phytohemagglutinins Proteins 0.000 description 4
239000002202 Polyethylene glycol Substances 0.000 description 4
108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 description 4
102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 description 4
206010038389 Renal cancer Diseases 0.000 description 4
208000006265 Renal cell carcinoma Diseases 0.000 description 4
206010039491 Sarcoma Diseases 0.000 description 4
230000006044 T cell activation Effects 0.000 description 4
230000006052 T cell proliferation Effects 0.000 description 4
206010042971 T-cell lymphoma Diseases 0.000 description 4
208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 4
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 4
239000003963 antioxidant agent Substances 0.000 description 4
235000006708 antioxidants Nutrition 0.000 description 4
239000002585 base Substances 0.000 description 4
230000015572 biosynthetic process Effects 0.000 description 4
239000006285 cell suspension Substances 0.000 description 4
238000005119 centrifugation Methods 0.000 description 4
239000007859 condensation product Substances 0.000 description 4
GGIMHJFVOMBCFX-UHFFFAOYSA-M cyanomethyl(trimethyl)phosphanium;iodide Chemical compound [I-].C[P+](C)(C)CC#N GGIMHJFVOMBCFX-UHFFFAOYSA-M 0.000 description 4
230000000779 depleting effect Effects 0.000 description 4
238000002474 experimental method Methods 0.000 description 4
238000000684 flow cytometry Methods 0.000 description 4
239000008187 granular material Substances 0.000 description 4
229930195733 hydrocarbon Natural products 0.000 description 4
150000003840 hydrochlorides Chemical class 0.000 description 4
230000003993 interaction Effects 0.000 description 4
201000010982 kidney cancer Diseases 0.000 description 4
201000007270 liver cancer Diseases 0.000 description 4
208000014018 liver neoplasm Diseases 0.000 description 4
201000000050 myeloid neoplasm Diseases 0.000 description 4
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 4
150000002825 nitriles Chemical class 0.000 description 4
244000052769 pathogen Species 0.000 description 4
230000037361 pathway Effects 0.000 description 4
239000003208 petroleum Substances 0.000 description 4
230000001885 phytohemagglutinin Effects 0.000 description 4
239000004417 polycarbonate Substances 0.000 description 4
229920001223 polyethylene glycol Polymers 0.000 description 4
239000001267 polyvinylpyrrolidone Substances 0.000 description 4
229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
229940002612 prodrug Drugs 0.000 description 4
239000000651 prodrug Substances 0.000 description 4
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
238000000746 purification Methods 0.000 description 4
239000000741 silica gel Substances 0.000 description 4
229910002027 silica gel Inorganic materials 0.000 description 4
235000009518 sodium iodide Nutrition 0.000 description 4
206010041823 squamous cell carcinoma Diseases 0.000 description 4
239000003381 stabilizer Substances 0.000 description 4
238000003756 stirring Methods 0.000 description 4
239000000375 suspending agent Substances 0.000 description 4
230000001225 therapeutic effect Effects 0.000 description 4
238000004704 ultra performance liquid chromatography Methods 0.000 description 4
229910052725 zinc Inorganic materials 0.000 description 4
239000011701 zinc Substances 0.000 description 4
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 3
YNSISXZRGHBBNJ-VQSPDULUSA-N 4-[(2S,5R)-4-[(4-chlorophenyl)-(4-fluorophenyl)methyl]-2,5-dimethylpiperazin-1-yl]-6-methoxy-1-methyl-1,5-naphthyridin-2-one Chemical compound ClC1=CC=C(C=C1)C(N1C[C@@H](N(C[C@H]1C)C1=CC(N(C2=CC=C(N=C12)OC)C)=O)C)C1=CC=C(C=C1)F YNSISXZRGHBBNJ-VQSPDULUSA-N 0.000 description 3
MBYXQDFRAYIYHX-QGZVFWFLSA-N 4-[(3R)-4-[bis(4-fluorophenyl)methyl]-3-methylpiperazin-1-yl]-6-bromo-1-methyl-2-oxo-1,5-naphthyridine-3-carbonitrile Chemical compound FC1=CC=C(C=C1)C(N1[C@@H](CN(CC1)C1=C(C(N(C2=CC=C(N=C12)Br)C)=O)C#N)C)C1=CC=C(C=C1)F MBYXQDFRAYIYHX-QGZVFWFLSA-N 0.000 description 3
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 3
SOCABYBFBPXOQI-HFHQHIJTSA-N 8-[(2S,5R)-4-[(4-fluorophenyl)-(4-methylphenyl)methyl]-2,5-dimethylpiperazin-1-yl]-5-methyl-6-oxo-1,5-naphthyridine-2-carbonitrile Chemical compound FC1=CC=C(C=C1)C(N1C[C@@H](N(C[C@H]1C)C1=CC(N(C=2C=CC(=NC1=2)C#N)C)=O)C)C1=CC=C(C=C1)C SOCABYBFBPXOQI-HFHQHIJTSA-N 0.000 description 3
RMSOVVQJHLVONE-CABCVRRESA-N 8-[(2S,5R)-4-[[2-(difluoromethyl)-4-fluorophenyl]methyl]-2,5-dimethylpiperazin-1-yl]-5-methyl-6-oxo-1,5-naphthyridine-2-carbonitrile Chemical compound FC(C1=C(C=CC(=C1)F)CN1C[C@@H](N(C[C@H]1C)C1=CC(N(C=2C=CC(=NC1=2)C#N)C)=O)C)F RMSOVVQJHLVONE-CABCVRRESA-N 0.000 description 3
RGCURDZJTFJFJK-UHFFFAOYSA-N 8-chloro-5-methyl-6-oxo-1,5-naphthyridine-2-carbonitrile Chemical compound ClC1=CC(N(C=2C=CC(=NC1=2)C#N)C)=O RGCURDZJTFJFJK-UHFFFAOYSA-N 0.000 description 3
AWDCPIDRXPAFAM-UHFFFAOYSA-N 8-hydroxy-5-methyl-6-oxo-1,5-naphthyridine-2-carbonitrile Chemical compound C1=C(C#N)N=C2C(O)=CC(=O)N(C)C2=C1 AWDCPIDRXPAFAM-UHFFFAOYSA-N 0.000 description 3
244000215068 Acacia senegal Species 0.000 description 3
208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 3
208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 3
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
238000011725 BALB/c mouse Methods 0.000 description 3
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
SHTGRVVURIUHTH-YPMHNXCESA-N C(C)[C@@H]1N(C[C@H](NC1)CC)C=1C2=C(N(C(N=1)=O)C)C=CC(=N2)C#N Chemical compound C(C)[C@@H]1N(C[C@H](NC1)CC)C=1C2=C(N(C(N=1)=O)C)C=CC(=N2)C#N SHTGRVVURIUHTH-YPMHNXCESA-N 0.000 description 3
XDJLIIDSRORSQS-WDEREUQCSA-N C(C)[C@H]1NC[C@@H](N(C1)C=1C2=C(N(C(N=1)=O)C)C=CC(=N2)C#N)C Chemical compound C(C)[C@H]1NC[C@@H](N(C1)C=1C2=C(N(C(N=1)=O)C)C=CC(=N2)C#N)C XDJLIIDSRORSQS-WDEREUQCSA-N 0.000 description 3
206010008342 Cervix carcinoma Diseases 0.000 description 3
101150086096 Eif2ak3 gene Proteins 0.000 description 3
241000400611 Eucalyptus deanei Species 0.000 description 3
229920000084 Gum arabic Polymers 0.000 description 3
101000834898 Homo sapiens Alpha-synuclein Proteins 0.000 description 3
101000652359 Homo sapiens Spermatogenesis-associated protein 2 Proteins 0.000 description 3
101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 3
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 3
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
239000007993 MOPS buffer Substances 0.000 description 3
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 3
239000007832 Na2SO4 Substances 0.000 description 3
239000012270 PD-1 inhibitor Substances 0.000 description 3
239000012668 PD-1-inhibitor Substances 0.000 description 3
235000019483 Peanut oil Nutrition 0.000 description 3
239000012979 RPMI medium Substances 0.000 description 3
208000005718 Stomach Neoplasms Diseases 0.000 description 3
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 3
208000024770 Thyroid neoplasm Diseases 0.000 description 3
208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 3
235000010489 acacia gum Nutrition 0.000 description 3
239000000205 acacia gum Substances 0.000 description 3
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
239000000654 additive Substances 0.000 description 3
235000010443 alginic acid Nutrition 0.000 description 3
229920000615 alginic acid Polymers 0.000 description 3
230000001668 ameliorated effect Effects 0.000 description 3
239000007864 aqueous solution Substances 0.000 description 3
125000004429 atom Chemical group 0.000 description 3
210000003719 b-lymphocyte Anatomy 0.000 description 3
238000004166 bioassay Methods 0.000 description 3
230000000903 blocking effect Effects 0.000 description 3
150000001649 bromium compounds Chemical class 0.000 description 3
239000000969 carrier Substances 0.000 description 3
238000012054 celltiter-glo Methods 0.000 description 3
229920002678 cellulose Polymers 0.000 description 3
210000003169 central nervous system Anatomy 0.000 description 3
201000010881 cervical cancer Diseases 0.000 description 3
230000008859 change Effects 0.000 description 3
239000003086 colorant Substances 0.000 description 3
238000011284 combination treatment Methods 0.000 description 3
230000000875 corresponding effect Effects 0.000 description 3
229940097362 cyclodextrins Drugs 0.000 description 3
239000002270 dispersing agent Substances 0.000 description 3
238000005516 engineering process Methods 0.000 description 3
239000003925 fat Substances 0.000 description 3
206010017758 gastric cancer Diseases 0.000 description 3
239000007903 gelatin capsule Substances 0.000 description 3
208000005017 glioblastoma Diseases 0.000 description 3
201000010536 head and neck cancer Diseases 0.000 description 3
208000014829 head and neck neoplasm Diseases 0.000 description 3
206010073071 hepatocellular carcinoma Diseases 0.000 description 3
231100000844 hepatocellular carcinoma Toxicity 0.000 description 3
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 3
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
238000009169 immunotherapy Methods 0.000 description 3
230000001976 improved effect Effects 0.000 description 3
150000004694 iodide salts Chemical class 0.000 description 3
150000002500 ions Chemical class 0.000 description 3
238000002955 isolation Methods 0.000 description 3
239000008101 lactose Substances 0.000 description 3
235000010445 lecithin Nutrition 0.000 description 3
239000000787 lecithin Substances 0.000 description 3
229940067606 lecithin Drugs 0.000 description 3
239000003446 ligand Substances 0.000 description 3
229940057995 liquid paraffin Drugs 0.000 description 3
238000004020 luminiscence type Methods 0.000 description 3
239000006166 lysate Substances 0.000 description 3
235000019359 magnesium stearate Nutrition 0.000 description 3
208000020968 mature T-cell and NK-cell non-Hodgkin lymphoma Diseases 0.000 description 3
239000004530 micro-emulsion Substances 0.000 description 3
238000010172 mouse model Methods 0.000 description 3
208000025113 myeloid leukemia Diseases 0.000 description 3
239000012299 nitrogen atmosphere Substances 0.000 description 3
239000000346 nonvolatile oil Substances 0.000 description 3
229940121655 pd-1 inhibitor Drugs 0.000 description 3
239000000312 peanut oil Substances 0.000 description 3
239000008188 pellet Substances 0.000 description 3
239000000546 pharmaceutical excipient Substances 0.000 description 3
239000010452 phosphate Substances 0.000 description 3
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
239000002953 phosphate buffered saline Substances 0.000 description 3
230000002335 preservative effect Effects 0.000 description 3
230000035755 proliferation Effects 0.000 description 3
230000001737 promoting effect Effects 0.000 description 3
125000006239 protecting group Chemical group 0.000 description 3
238000000159 protein binding assay Methods 0.000 description 3
230000004044 response Effects 0.000 description 3
229920006395 saturated elastomer Polymers 0.000 description 3
230000028327 secretion Effects 0.000 description 3
230000019491 signal transduction Effects 0.000 description 3
239000011734 sodium Substances 0.000 description 3
235000017557 sodium bicarbonate Nutrition 0.000 description 3
229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
230000003381 solubilizing effect Effects 0.000 description 3
210000000130 stem cell Anatomy 0.000 description 3
201000011549 stomach cancer Diseases 0.000 description 3
201000002510 thyroid cancer Diseases 0.000 description 3
238000002054 transplantation Methods 0.000 description 3
239000001993 wax Substances 0.000 description 3
GTLDTDOJJJZVBW-UHFFFAOYSA-N zinc cyanide Chemical compound [Zn+2].N#[C-].N#[C-] GTLDTDOJJJZVBW-UHFFFAOYSA-N 0.000 description 3
JVJGCCBAOOWGEO-RUTPOYCXSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-4-amino-2-[[(2s,3s)-2-[[(2s,3s)-2-[[(2s)-2-azaniumyl-3-hydroxypropanoyl]amino]-3-methylpentanoyl]amino]-3-methylpentanoyl]amino]-4-oxobutanoyl]amino]-3-phenylpropanoyl]amino]-4-carboxylatobutanoyl]amino]-6-azaniumy Chemical compound OC[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O)CC1=CC=CC=C1 JVJGCCBAOOWGEO-RUTPOYCXSA-N 0.000 description 2
QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 2
RUPDLRIDZKCKHV-UHFFFAOYSA-N (4-fluorophenyl)-(4-methylphenyl)methanol Chemical compound C1=CC(C)=CC=C1C(O)C1=CC=C(F)C=C1 RUPDLRIDZKCKHV-UHFFFAOYSA-N 0.000 description 2
IDTHJDQLBCJIKB-UHFFFAOYSA-N (6-bromo-3-cyano-1-methyl-2-oxo-1,5-naphthyridin-4-yl) trifluoromethanesulfonate Chemical compound FC(S(=O)(=O)OC1=C(C(N(C2=CC=C(N=C12)Br)C)=O)C#N)(F)F IDTHJDQLBCJIKB-UHFFFAOYSA-N 0.000 description 2
MSBYDHLVQAZHJP-UHFFFAOYSA-N (6-cyano-1-methyl-2-oxo-1,5-naphthyridin-4-yl) trifluoromethanesulfonate Chemical compound FC(S(=O)(=O)OC1=CC(N(C2=CC=C(N=C12)C#N)C)=O)(F)F MSBYDHLVQAZHJP-UHFFFAOYSA-N 0.000 description 2
WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 2
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
VFWCMGCRMGJXDK-UHFFFAOYSA-N 1-chlorobutane Chemical class CCCCCl VFWCMGCRMGJXDK-UHFFFAOYSA-N 0.000 description 2
IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 2
VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
CQZCBLLPJONWCZ-UHFFFAOYSA-N 2,2-dimethylpiperazine-1-carboxylic acid Chemical compound CC1(C)CNCCN1C(O)=O CQZCBLLPJONWCZ-UHFFFAOYSA-N 0.000 description 2
IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
MIMSHWAQHZOTJK-ZQIYAJFXSA-N 8-[(2S,5R)-4-[1-(2,4-difluorophenyl)propyl]-2,5-dimethylpiperazin-1-yl]-5-methyl-6-oxo-1,5-naphthyridine-2-carbonitrile Chemical compound FC1=C(C=CC(=C1)F)C(CC)N1C[C@@H](N(C[C@H]1C)C1=CC(N(C=2C=CC(=NC1=2)C#N)C)=O)C MIMSHWAQHZOTJK-ZQIYAJFXSA-N 0.000 description 2
JSDWTOGDZIDOQE-YSPPHNQVSA-N 8-[(2S,5R)-4-[1-(2,6-difluorophenyl)ethyl]-2,5-dimethylpiperazin-1-yl]-5-methyl-6-oxo-1,5-naphthyridine-2-carbonitrile Chemical compound FC1=C(C(=CC=C1)F)C(C)N1C[C@@H](N(C[C@H]1C)C1=CC(N(C=2C=CC(=NC1=2)C#N)C)=O)C JSDWTOGDZIDOQE-YSPPHNQVSA-N 0.000 description 2
AOJMESHAHMSPRC-UHFFFAOYSA-N 8-chloro-5-methyl-7-nitro-6-oxo-1,5-naphthyridine-2-carbonitrile Chemical compound ClC1=C(C(N(C=2C=CC(=NC1=2)C#N)C)=O)[N+](=O)[O-] AOJMESHAHMSPRC-UHFFFAOYSA-N 0.000 description 2
QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
241000416162 Astragalus gummifer Species 0.000 description 2
206010003571 Astrocytoma Diseases 0.000 description 2
208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 2
208000003950 B-cell lymphoma Diseases 0.000 description 2
206010005003 Bladder cancer Diseases 0.000 description 2
NYMXRBNYRPUQSU-UHFFFAOYSA-N BrC(C1=NC=C(C=C1)C(F)(F)F)C1=CC=C(C=C1)F Chemical compound BrC(C1=NC=C(C=C1)C(F)(F)F)C1=CC=C(C=C1)F NYMXRBNYRPUQSU-UHFFFAOYSA-N 0.000 description 2
208000003174 Brain Neoplasms Diseases 0.000 description 2
206010006187 Breast cancer Diseases 0.000 description 2
208000026310 Breast neoplasm Diseases 0.000 description 2
MVPFPBIHUUHXGU-LKXRKSRJSA-N C(C)[C@@H]1N(C[C@H](N(C1)C(CC)C1=CC=C(C=C1)C(F)(F)F)CC)C=1C2=C(N(C(N=1)=O)C)C=CC(=N2)C#N Chemical compound C(C)[C@@H]1N(C[C@H](N(C1)C(CC)C1=CC=C(C=C1)C(F)(F)F)CC)C=1C2=C(N(C(N=1)=O)C)C=CC(=N2)C#N MVPFPBIHUUHXGU-LKXRKSRJSA-N 0.000 description 2
RYANVYSVCYNQFK-AXWGZAFASA-N C(C)[C@@H]1N(C[C@H](N(C1)C(CCC)C1=CC=C(C=C1)C(F)(F)F)CC)C=1C2=C(N(C(N=1)=O)C)C=CC(=N2)C#N Chemical compound C(C)[C@@H]1N(C[C@H](N(C1)C(CCC)C1=CC=C(C=C1)C(F)(F)F)CC)C=1C2=C(N(C(N=1)=O)C)C=CC(=N2)C#N RYANVYSVCYNQFK-AXWGZAFASA-N 0.000 description 2
AIVDFWPDLDQNIT-XNKIQEMOSA-N C(C)[C@H]1N(C[C@@H](N(C1)C=1C2=C(N(C(N=1)=O)C)C=CC(=N2)C#N)C)C(C)C1=CC=C(C=C1)C(F)(F)F Chemical compound C(C)[C@H]1N(C[C@@H](N(C1)C=1C2=C(N(C(N=1)=O)C)C=CC(=N2)C#N)C)C(C)C1=CC=C(C=C1)C(F)(F)F AIVDFWPDLDQNIT-XNKIQEMOSA-N 0.000 description 2
NALBGDIPGZZNPU-QOKSPTNUSA-N C(C)[C@H]1N(C[C@@H](N(C1)C=1C2=C(N(C(N=1)=O)C)C=CC(=N2)C#N)C)C(C1=NC=C(C=C1)C(F)(F)F)C1=CC=C(C=C1)F Chemical compound C(C)[C@H]1N(C[C@@H](N(C1)C=1C2=C(N(C(N=1)=O)C)C=CC(=N2)C#N)C)C(C1=NC=C(C=C1)C(F)(F)F)C1=CC=C(C=C1)F NALBGDIPGZZNPU-QOKSPTNUSA-N 0.000 description 2
IEZDDWFKFGQJKD-YMOPUJOUSA-N C1(CC1)C1=NOC(=N1)C(N1C[C@@H](N(C[C@H]1C)C=1C2=C(N(C(N=1)=O)C)C=CC(=N2)C#N)C)C1=CC=C(C=C1)F Chemical compound C1(CC1)C1=NOC(=N1)C(N1C[C@@H](N(C[C@H]1C)C=1C2=C(N(C(N=1)=O)C)C=CC(=N2)C#N)C)C1=CC=C(C=C1)F IEZDDWFKFGQJKD-YMOPUJOUSA-N 0.000 description 2
BZTXHSBPBUQZBK-SGNGHUOJSA-N C1(CC1)COC1=CC(=C(C=C1)C(CC)N1C[C@@H](N(C[C@H]1CC)C=1C2=C(N(C(N=1)=O)C)C=CC(=N2)C#N)CC)F Chemical compound C1(CC1)COC1=CC(=C(C=C1)C(CC)N1C[C@@H](N(C[C@H]1CC)C=1C2=C(N(C(N=1)=O)C)C=CC(=N2)C#N)CC)F BZTXHSBPBUQZBK-SGNGHUOJSA-N 0.000 description 2
MWXULEFQPDWBBB-DSSITSQDSA-N CN1C(N=C(C2=C1C=CC(=N2)C#N)N1[C@H](CN([C@@H](C1)CCC)C(C)C1=CC=C(C=C1)C(F)(F)F)C)=O Chemical compound CN1C(N=C(C2=C1C=CC(=N2)C#N)N1[C@H](CN([C@@H](C1)CCC)C(C)C1=CC=C(C=C1)C(F)(F)F)C)=O MWXULEFQPDWBBB-DSSITSQDSA-N 0.000 description 2
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
206010008583 Chloroma Diseases 0.000 description 2
SFOYAEPGELLULI-UHFFFAOYSA-N ClC(CC)C1=C(C=C(C=C1)OCC1CC1)F Chemical compound ClC(CC)C1=C(C=C(C=C1)OCC1CC1)F SFOYAEPGELLULI-UHFFFAOYSA-N 0.000 description 2
FZAWIXYDKIIODN-CUDINMHHSA-N ClC1=CC=C(C=C1)C(N1C[C@@H](N(C[C@H]1CC)C=1C2=C(N(C(N=1)=O)C)C=CC(=N2)C#N)C)C1=NC=CC=C1 Chemical compound ClC1=CC=C(C=C1)C(N1C[C@@H](N(C[C@H]1CC)C=1C2=C(N(C(N=1)=O)C)C=CC(=N2)C#N)C)C1=NC=CC=C1 FZAWIXYDKIIODN-CUDINMHHSA-N 0.000 description 2
208000001333 Colorectal Neoplasms Diseases 0.000 description 2
229940126639 Compound 33 Drugs 0.000 description 2
102000004127 Cytokines Human genes 0.000 description 2
108090000695 Cytokines Proteins 0.000 description 2
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 2
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
208000000461 Esophageal Neoplasms Diseases 0.000 description 2
XNOWKAWYXXGCHS-VRBVYGAASA-N FC1=CC=C(C=C1)C(N1C[C@@H](N(C[C@H]1C)C=1C2=C(N(C(N=1)=O)C)C=CC(=N2)C#N)C)C1=NC=C(C=C1)C(F)(F)F Chemical compound FC1=CC=C(C=C1)C(N1C[C@@H](N(C[C@H]1C)C=1C2=C(N(C(N=1)=O)C)C=CC(=N2)C#N)C)C1=NC=C(C=C1)C(F)(F)F XNOWKAWYXXGCHS-VRBVYGAASA-N 0.000 description 2
201000008808 Fibrosarcoma Diseases 0.000 description 2
206010017993 Gastrointestinal neoplasms Diseases 0.000 description 2
108010010803 Gelatin Proteins 0.000 description 2
241000224466 Giardia Species 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
208000002250 Hematologic Neoplasms Diseases 0.000 description 2
241000238631 Hexapoda Species 0.000 description 2
208000017604 Hodgkin disease Diseases 0.000 description 2
208000021519 Hodgkin lymphoma Diseases 0.000 description 2
208000010747 Hodgkins lymphoma Diseases 0.000 description 2
208000006404 Large Granular Lymphocytic Leukemia Diseases 0.000 description 2
241000222722 Leishmania <genus> Species 0.000 description 2
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
108091054437 MHC class I family Proteins 0.000 description 2
102000043129 MHC class I family Human genes 0.000 description 2
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
241000124008 Mammalia Species 0.000 description 2
229920000168 Microcrystalline cellulose Polymers 0.000 description 2
241001529936 Murinae Species 0.000 description 2
101100222220 Mus musculus Ctla4 gene Proteins 0.000 description 2
101001034843 Mus musculus Interferon-induced transmembrane protein 1 Proteins 0.000 description 2
125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 2
WAVCYJTTZBZHFR-UHFFFAOYSA-N N1=C(C=CC=2NCC=CC12)C#N Chemical compound N1=C(C=CC=2NCC=CC12)C#N WAVCYJTTZBZHFR-UHFFFAOYSA-N 0.000 description 2
PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
206010029461 Nodal marginal zone B-cell lymphomas Diseases 0.000 description 2
206010030155 Oesophageal carcinoma Diseases 0.000 description 2
239000005642 Oleic acid Substances 0.000 description 2
ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
240000007594 Oryza sativa Species 0.000 description 2
108010058846 Ovalbumin Proteins 0.000 description 2
206010033128 Ovarian cancer Diseases 0.000 description 2
206010061535 Ovarian neoplasm Diseases 0.000 description 2
206010061902 Pancreatic neoplasm Diseases 0.000 description 2
208000027190 Peripheral T-cell lymphomas Diseases 0.000 description 2
108091000080 Phosphotransferase Proteins 0.000 description 2
208000007913 Pituitary Neoplasms Diseases 0.000 description 2
239000004698 Polyethylene Substances 0.000 description 2
208000009052 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 2
206010060862 Prostate cancer Diseases 0.000 description 2
208000000236 Prostatic Neoplasms Diseases 0.000 description 2
206010070308 Refractory cancer Diseases 0.000 description 2
229920002684 Sepharose Polymers 0.000 description 2
PNUZDKCDAWUEGK-CYZMBNFOSA-N Sitafloxacin Chemical compound C([C@H]1N)N(C=2C(=C3C(C(C(C(O)=O)=CN3[C@H]3[C@H](C3)F)=O)=CC=2F)Cl)CC11CC1 PNUZDKCDAWUEGK-CYZMBNFOSA-N 0.000 description 2
206010041067 Small cell lung cancer Diseases 0.000 description 2
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
208000021712 Soft tissue sarcoma Diseases 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
235000021355 Stearic acid Nutrition 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
230000005867 T cell response Effects 0.000 description 2
208000031672 T-Cell Peripheral Lymphoma Diseases 0.000 description 2
201000008717 T-cell large granular lymphocyte leukemia Diseases 0.000 description 2
208000026651 T-cell prolymphocytic leukemia Diseases 0.000 description 2
208000020982 T-lymphoblastic lymphoma Diseases 0.000 description 2
DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
208000024313 Testicular Neoplasms Diseases 0.000 description 2
206010057644 Testis cancer Diseases 0.000 description 2
229920001615 Tragacanth Polymers 0.000 description 2
HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 2
102000004142 Trypsin Human genes 0.000 description 2
108090000631 Trypsin Proteins 0.000 description 2
208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 2
208000002495 Uterine Neoplasms Diseases 0.000 description 2
206010047741 Vulval cancer Diseases 0.000 description 2
208000004354 Vulvar Neoplasms Diseases 0.000 description 2
SMNRFWMNPDABKZ-WVALLCKVSA-N [[(2R,3S,4R,5S)-5-(2,6-dioxo-3H-pyridin-3-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4S,5R,6R)-4-fluoro-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)C2C=CC(=O)NC2=O)[C@H](O)[C@@H](F)[C@@H]1O SMNRFWMNPDABKZ-WVALLCKVSA-N 0.000 description 2
150000001242 acetic acid derivatives Chemical class 0.000 description 2
230000001154 acute effect Effects 0.000 description 2
210000005006 adaptive immune system Anatomy 0.000 description 2
239000000783 alginic acid Substances 0.000 description 2
229960001126 alginic acid Drugs 0.000 description 2
150000004781 alginic acids Chemical class 0.000 description 2
125000001931 aliphatic group Chemical group 0.000 description 2
230000000735 allogeneic effect Effects 0.000 description 2
150000001408 amides Chemical class 0.000 description 2
150000001412 amines Chemical class 0.000 description 2
125000004103 aminoalkyl group Chemical group 0.000 description 2
230000005809 anti-tumor immunity Effects 0.000 description 2
230000005875 antibody response Effects 0.000 description 2
235000010323 ascorbic acid Nutrition 0.000 description 2
239000012131 assay buffer Substances 0.000 description 2
HTZCNXWZYVXIMZ-UHFFFAOYSA-M benzyl(triethyl)azanium;chloride Chemical compound [Cl-].CC[N+](CC)(CC)CC1=CC=CC=C1 HTZCNXWZYVXIMZ-UHFFFAOYSA-M 0.000 description 2
WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
239000006227 byproduct Substances 0.000 description 2
229910052791 calcium Inorganic materials 0.000 description 2
239000011575 calcium Substances 0.000 description 2
229910000019 calcium carbonate Inorganic materials 0.000 description 2
235000010216 calcium carbonate Nutrition 0.000 description 2
239000001110 calcium chloride Substances 0.000 description 2
235000011148 calcium chloride Nutrition 0.000 description 2
229910001628 calcium chloride Inorganic materials 0.000 description 2
239000001506 calcium phosphate Substances 0.000 description 2
229910000389 calcium phosphate Inorganic materials 0.000 description 2
235000011010 calcium phosphates Nutrition 0.000 description 2
238000002619 cancer immunotherapy Methods 0.000 description 2
239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
239000001768 carboxy methyl cellulose Substances 0.000 description 2
150000007942 carboxylates Chemical class 0.000 description 2
230000003915 cell function Effects 0.000 description 2
230000022534 cell killing Effects 0.000 description 2
238000001516 cell proliferation assay Methods 0.000 description 2
230000003833 cell viability Effects 0.000 description 2
235000010980 cellulose Nutrition 0.000 description 2
239000001913 cellulose Substances 0.000 description 2
201000010897 colon adenocarcinoma Diseases 0.000 description 2
238000004440 column chromatography Methods 0.000 description 2
229940125904 compound 1 Drugs 0.000 description 2
229940125773 compound 10 Drugs 0.000 description 2
229940125782 compound 2 Drugs 0.000 description 2
229940126214 compound 3 Drugs 0.000 description 2
229940125898 compound 5 Drugs 0.000 description 2
238000007796 conventional method Methods 0.000 description 2
238000012258 culturing Methods 0.000 description 2
230000006378 damage Effects 0.000 description 2
150000001982 diacylglycerols Chemical class 0.000 description 2
239000007884 disintegrant Substances 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
210000003162 effector t lymphocyte Anatomy 0.000 description 2
238000003821 enantio-separation Methods 0.000 description 2
230000002708 enhancing effect Effects 0.000 description 2
201000004101 esophageal cancer Diseases 0.000 description 2
KUULXNYSTCUJJX-UHFFFAOYSA-N ethyl 3-[acetyl(methyl)amino]-6-cyanopyridine-2-carboxylate Chemical compound C(#N)C1=CC=C(C(=N1)C(=O)OCC)N(C(C)=O)C KUULXNYSTCUJJX-UHFFFAOYSA-N 0.000 description 2
230000007717 exclusion Effects 0.000 description 2
239000000706 filtrate Substances 0.000 description 2
125000001153 fluoro group Chemical group F* 0.000 description 2
238000004108 freeze drying Methods 0.000 description 2
125000000524 functional group Chemical group 0.000 description 2
239000008273 gelatin Substances 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
235000011852 gelatine desserts Nutrition 0.000 description 2
230000012010 growth Effects 0.000 description 2
201000005787 hematologic cancer Diseases 0.000 description 2
208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 2
208000006454 hepatitis Diseases 0.000 description 2
231100000283 hepatitis Toxicity 0.000 description 2
BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
150000004677 hydrates Chemical class 0.000 description 2
239000001257 hydrogen Substances 0.000 description 2
125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
239000002584 immunological anticancer agent Substances 0.000 description 2
230000001506 immunosuppresive effect Effects 0.000 description 2
239000007943 implant Substances 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
239000004615 ingredient Substances 0.000 description 2
230000014828 interferon-gamma production Effects 0.000 description 2
QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 2
229910052744 lithium Inorganic materials 0.000 description 2
239000000314 lubricant Substances 0.000 description 2
201000011649 lymphoblastic lymphoma Diseases 0.000 description 2
201000007919 lymphoplasmacytic lymphoma Diseases 0.000 description 2
229910001629 magnesium chloride Inorganic materials 0.000 description 2
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
201000008806 mesenchymal cell neoplasm Diseases 0.000 description 2
235000019813 microcrystalline cellulose Nutrition 0.000 description 2
239000008108 microcrystalline cellulose Substances 0.000 description 2
229940016286 microcrystalline cellulose Drugs 0.000 description 2
239000002480 mineral oil Substances 0.000 description 2
239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
201000005962 mycosis fungoides Diseases 0.000 description 2
201000005987 myeloid sarcoma Diseases 0.000 description 2
102000039446 nucleic acids Human genes 0.000 description 2
108020004707 nucleic acids Proteins 0.000 description 2
150000007523 nucleic acids Chemical class 0.000 description 2
239000002773 nucleotide Substances 0.000 description 2
125000003729 nucleotide group Chemical group 0.000 description 2
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
HEGSGKPQLMEBJL-RKQHYHRCSA-N octyl beta-D-glucopyranoside Chemical compound CCCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HEGSGKPQLMEBJL-RKQHYHRCSA-N 0.000 description 2
235000014593 oils and fats Nutrition 0.000 description 2
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
239000004006 olive oil Substances 0.000 description 2
235000008390 olive oil Nutrition 0.000 description 2
229940092253 ovalbumin Drugs 0.000 description 2
201000002528 pancreatic cancer Diseases 0.000 description 2
208000008443 pancreatic carcinoma Diseases 0.000 description 2
230000001717 pathogenic effect Effects 0.000 description 2
150000003013 phosphoric acid derivatives Chemical class 0.000 description 2
XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
102000020233 phosphotransferase Human genes 0.000 description 2
239000008389 polyethoxylated castor oil Substances 0.000 description 2
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
229920000053 polysorbate 80 Polymers 0.000 description 2
102000004196 processed proteins & peptides Human genes 0.000 description 2
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
230000009467 reduction Effects 0.000 description 2
208000016691 refractory malignant neoplasm Diseases 0.000 description 2
210000003289 regulatory T cell Anatomy 0.000 description 2
201000006845 reticulosarcoma Diseases 0.000 description 2
208000029922 reticulum cell sarcoma Diseases 0.000 description 2
201000009410 rhabdomyosarcoma Diseases 0.000 description 2
238000000926 separation method Methods 0.000 description 2
208000000587 small cell lung carcinoma Diseases 0.000 description 2
150000003384 small molecules Chemical class 0.000 description 2
208000010721 smoldering plasma cell myeloma Diseases 0.000 description 2
235000010413 sodium alginate Nutrition 0.000 description 2
239000000661 sodium alginate Substances 0.000 description 2
229940005550 sodium alginate Drugs 0.000 description 2
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
239000007790 solid phase Substances 0.000 description 2
235000011069 sorbitan monooleate Nutrition 0.000 description 2
239000001593 sorbitan monooleate Substances 0.000 description 2
229940035049 sorbitan monooleate Drugs 0.000 description 2
210000004988 splenocyte Anatomy 0.000 description 2
239000008107 starch Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
239000008117 stearic acid Substances 0.000 description 2
239000011550 stock solution Substances 0.000 description 2
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
238000004808 supercritical fluid chromatography Methods 0.000 description 2
239000004094 surface-active agent Substances 0.000 description 2
239000000454 talc Substances 0.000 description 2
229910052623 talc Inorganic materials 0.000 description 2
235000012222 talc Nutrition 0.000 description 2
229940066453 tecentriq Drugs 0.000 description 2
AQPSRJCLHXYAPC-UONOGXRCSA-N tert-butyl (2R,5S)-4-(6-cyano-1-methyl-2-oxo-1,5-naphthyridin-4-yl)-2,5-dimethylpiperazine-1-carboxylate Chemical compound C(#N)C=1N=C2C(=CC(N(C2=CC=1)C)=O)N1C[C@H](N(C[C@@H]1C)C(=O)OC(C)(C)C)C AQPSRJCLHXYAPC-UONOGXRCSA-N 0.000 description 2
201000003120 testicular cancer Diseases 0.000 description 2
HLZKNKRTKFSKGZ-UHFFFAOYSA-N tetradecan-1-ol Chemical compound CCCCCCCCCCCCCCO HLZKNKRTKFSKGZ-UHFFFAOYSA-N 0.000 description 2
229940124597 therapeutic agent Drugs 0.000 description 2
AOBORMOPSGHCAX-DGHZZKTQSA-N tocofersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-DGHZZKTQSA-N 0.000 description 2
229960000984 tocofersolan Drugs 0.000 description 2
231100000419 toxicity Toxicity 0.000 description 2
230000001988 toxicity Effects 0.000 description 2
239000003053 toxin Substances 0.000 description 2
231100000765 toxin Toxicity 0.000 description 2
108700012359 toxins Proteins 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
YWWDBCBWQNCYNR-UHFFFAOYSA-N trimethylphosphine Chemical compound CP(C)C YWWDBCBWQNCYNR-UHFFFAOYSA-N 0.000 description 2
239000012588 trypsin Substances 0.000 description 2
229960001005 tuberculin Drugs 0.000 description 2
241000701447 unidentified baculovirus Species 0.000 description 2
201000005112 urinary bladder cancer Diseases 0.000 description 2
206010046766 uterine cancer Diseases 0.000 description 2
229960005486 vaccine Drugs 0.000 description 2
235000015112 vegetable and seed oil Nutrition 0.000 description 2
239000008158 vegetable oil Substances 0.000 description 2
201000005102 vulva cancer Diseases 0.000 description 2
238000005406 washing Methods 0.000 description 2
239000002076 α-tocopherol Substances 0.000 description 2
235000004835 α-tocopherol Nutrition 0.000 description 2
LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical compound CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
UAOUIVVJBYDFKD-XKCDOFEDSA-N (1R,9R,10S,11R,12R,15S,18S,21R)-10,11,21-trihydroxy-8,8-dimethyl-14-methylidene-4-(prop-2-enylamino)-20-oxa-5-thia-3-azahexacyclo[9.7.2.112,15.01,9.02,6.012,18]henicosa-2(6),3-dien-13-one Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(N=C(NCC=C)S4)=C4CC(C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 UAOUIVVJBYDFKD-XKCDOFEDSA-N 0.000 description 1
AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 1
SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 1
GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 1
IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 1
MZQRXCOFRPWTPC-UHFFFAOYSA-N (4-fluorophenyl)-phenylmethanol Chemical compound C=1C=C(F)C=CC=1C(O)C1=CC=CC=C1 MZQRXCOFRPWTPC-UHFFFAOYSA-N 0.000 description 1
HEYONDYPXIUDCK-UHFFFAOYSA-L (5-diphenylphosphanyl-9,9-dimethylxanthen-4-yl)-diphenylphosphane;palladium(2+);dichloride Chemical compound Cl[Pd]Cl.C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 HEYONDYPXIUDCK-UHFFFAOYSA-L 0.000 description 1
GVJHHUAWPYXKBD-IEOSBIPESA-N (R)-alpha-Tocopherol Natural products OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 1
PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 1
TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
VVVIEAMNBUJAAP-UHFFFAOYSA-N 1-(1-bromopropyl)-2,4-difluorobenzene Chemical compound CCC(Br)C1=CC=C(F)C=C1F VVVIEAMNBUJAAP-UHFFFAOYSA-N 0.000 description 1
CKKMRMKMZIDSDS-UHFFFAOYSA-N 1-(1-chloroethyl)-4-(trifluoromethyl)benzene Chemical compound CC(Cl)C1=CC=C(C(F)(F)F)C=C1 CKKMRMKMZIDSDS-UHFFFAOYSA-N 0.000 description 1
RQZLYAGTUOUCHP-UHFFFAOYSA-N 1-(1-chloropropyl)-4-(trifluoromethyl)benzene Chemical compound CCC(Cl)c1ccc(cc1)C(F)(F)F RQZLYAGTUOUCHP-UHFFFAOYSA-N 0.000 description 1
KQZLRWGGWXJPOS-NLFPWZOASA-N 1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-6-[(4S,5R)-4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methylcyclohexen-1-yl]pyrazolo[3,4-b]pyrazine-3-carbonitrile Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](C)N1N=C(C=2C1=NC(=CN=2)C1=CC[C@@H]([C@@H](C1)C)N1[C@@H](CCC1)CO)C#N KQZLRWGGWXJPOS-NLFPWZOASA-N 0.000 description 1
WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 description 1
UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 1
TTXIFFYPVGWLSE-UHFFFAOYSA-N 1-[bis(4-fluorophenyl)methyl]piperazine Chemical compound C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)N1CCNCC1 TTXIFFYPVGWLSE-UHFFFAOYSA-N 0.000 description 1
LXQSWJLGGRQNPZ-UHFFFAOYSA-N 1-[bromo-(4-chlorophenyl)methyl]-4-fluorobenzene Chemical compound C1=CC(F)=CC=C1C(Br)C1=CC=C(Cl)C=C1 LXQSWJLGGRQNPZ-UHFFFAOYSA-N 0.000 description 1
VUQPJRPDRDVQMN-UHFFFAOYSA-N 1-chlorooctadecane Chemical class CCCCCCCCCCCCCCCCCCCl VUQPJRPDRDVQMN-UHFFFAOYSA-N 0.000 description 1
JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
AUOQUJCFZDEZSW-UHFFFAOYSA-N 2-(difluoromethyl)-4-fluorobenzaldehyde Chemical compound FC(F)C1=CC(F)=CC=C1C=O AUOQUJCFZDEZSW-UHFFFAOYSA-N 0.000 description 1
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
QWEAZSCWMWATDV-UHFFFAOYSA-N 2-[bromo-(4-chlorophenyl)methyl]pyridine Chemical compound C1=CC(Cl)=CC=C1C(Br)C1=CC=CC=N1 QWEAZSCWMWATDV-UHFFFAOYSA-N 0.000 description 1
YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 1
TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 description 1
125000006176 2-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 description 1
VODKOOOHHCAWFR-UHFFFAOYSA-N 2-iodoacetonitrile Chemical compound ICC#N VODKOOOHHCAWFR-UHFFFAOYSA-N 0.000 description 1
125000005916 2-methylpentyl group Chemical group 0.000 description 1
229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
WMPPDTMATNBGJN-UHFFFAOYSA-N 2-phenylethylbromide Chemical class BrCCC1=CC=CC=C1 WMPPDTMATNBGJN-UHFFFAOYSA-N 0.000 description 1
125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 1
QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 description 1
125000005917 3-methylpentyl group Chemical group 0.000 description 1
XMIIGOLPHOKFCH-UHFFFAOYSA-M 3-phenylpropionate Chemical compound [O-]C(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-M 0.000 description 1
XNYXOIVVYCPDGO-MNOVXSKESA-N 4-[(2S,5R)-2,5-dimethylpiperazin-1-yl]-6-methoxy-1-methyl-1,5-naphthyridin-2-one Chemical compound C[C@@H]1N(C[C@H](NC1)C)C1=CC(N(C2=CC=C(N=C12)OC)C)=O XNYXOIVVYCPDGO-MNOVXSKESA-N 0.000 description 1
APRZHQXAAWPYHS-UHFFFAOYSA-N 4-[5-[3-(carboxymethoxy)phenyl]-3-(4,5-dimethyl-1,3-thiazol-2-yl)tetrazol-3-ium-2-yl]benzenesulfonate Chemical compound S1C(C)=C(C)N=C1[N+]1=NC(C=2C=C(OCC(O)=O)C=CC=2)=NN1C1=CC=C(S([O-])(=O)=O)C=C1 APRZHQXAAWPYHS-UHFFFAOYSA-N 0.000 description 1
125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
SBFXTRNCOXYUGX-XWZNDSGVSA-N 8-[(2S,5R)-4-[(4-chlorophenyl)-(5-methylpyridin-2-yl)methyl]-2,5-dimethylpiperazin-1-yl]-5-methyl-6-oxo-1,5-naphthyridine-2-carbonitrile Chemical compound ClC1=CC=C(C=C1)C(N1C[C@@H](N(C[C@H]1C)C1=CC(N(C=2C=CC(=NC1=2)C#N)C)=O)C)C1=NC=C(C=C1)C SBFXTRNCOXYUGX-XWZNDSGVSA-N 0.000 description 1
IHAKTCHRYGNDMD-XZOQPEGZSA-N 8-[(2S,5R)-4-[bis(4-methylphenyl)methyl]-2,5-dimethylpiperazin-1-yl]-5-methyl-6-oxo-1,5-naphthyridine-2-carbonitrile Chemical compound CC1=CC=C(C=C1)C(N1C[C@@H](N(C[C@H]1C)C1=CC(N(C=2C=CC(=NC1=2)C#N)C)=O)C)C1=CC=C(C=C1)C IHAKTCHRYGNDMD-XZOQPEGZSA-N 0.000 description 1
DERMOPPXUJGXBT-SIHBAMTISA-N 8-[(3R)-4-[(4-chlorophenyl)-(5-fluoropyridin-2-yl)methyl]-3-methylpiperazin-1-yl]-5-methyl-6-oxo-1,5-naphthyridine-2,7-dicarbonitrile Chemical compound ClC1=CC=C(C=C1)C(N1[C@@H](CN(CC1)C1=C(C(N(C=2C=CC(=NC1=2)C#N)C)=O)C#N)C)C1=NC=C(C=C1)F DERMOPPXUJGXBT-SIHBAMTISA-N 0.000 description 1
241000224422 Acanthamoeba Species 0.000 description 1
206010000830 Acute leukaemia Diseases 0.000 description 1
208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 1
208000010507 Adenocarcinoma of Lung Diseases 0.000 description 1
208000016683 Adult T-cell leukemia/lymphoma Diseases 0.000 description 1
229920001450 Alpha-Cyclodextrin Polymers 0.000 description 1
239000005995 Aluminium silicate Substances 0.000 description 1
206010061424 Anal cancer Diseases 0.000 description 1
206010073478 Anaplastic large-cell lymphoma Diseases 0.000 description 1
241001465677 Ancylostomatoidea Species 0.000 description 1
206010002412 Angiocentric lymphomas Diseases 0.000 description 1
208000007860 Anus Neoplasms Diseases 0.000 description 1
235000017060 Arachis glabrata Nutrition 0.000 description 1
244000105624 Arachis hypogaea Species 0.000 description 1
235000010777 Arachis hypogaea Nutrition 0.000 description 1
235000018262 Arachis monticola Nutrition 0.000 description 1
208000006400 Arbovirus Encephalitis Diseases 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
108010011485 Aspartame Proteins 0.000 description 1
241000228212 Aspergillus Species 0.000 description 1
208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
241000223848 Babesia microti Species 0.000 description 1
241000193830 Bacillus <bacterium> Species 0.000 description 1
241000193738 Bacillus anthracis Species 0.000 description 1
241001235572 Balantioides coli Species 0.000 description 1
206010004593 Bile duct cancer Diseases 0.000 description 1
241000228405 Blastomyces dermatitidis Species 0.000 description 1
102000004506 Blood Proteins Human genes 0.000 description 1
108010017384 Blood Proteins Proteins 0.000 description 1
206010005949 Bone cancer Diseases 0.000 description 1
208000018084 Bone neoplasm Diseases 0.000 description 1
BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
206010006143 Brain stem glioma Diseases 0.000 description 1
208000011691 Burkitt lymphomas Diseases 0.000 description 1
FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
MVPFPBIHUUHXGU-FSSWDIPSSA-N C(C)[C@@H]1N(C[C@H](N(C1)[C@@H](CC)C1=CC=C(C=C1)C(F)(F)F)CC)C=1C2=C(N(C(N=1)=O)C)C=CC(=N2)C#N Chemical compound C(C)[C@@H]1N(C[C@H](N(C1)[C@@H](CC)C1=CC=C(C=C1)C(F)(F)F)CC)C=1C2=C(N(C(N=1)=O)C)C=CC(=N2)C#N MVPFPBIHUUHXGU-FSSWDIPSSA-N 0.000 description 1
RYANVYSVCYNQFK-VJBWXMMDSA-N C(C)[C@@H]1N(C[C@H](N(C1)[C@@H](CCC)C1=CC=C(C=C1)C(F)(F)F)CC)C=1C2=C(N(C(N=1)=O)C)C=CC(=N2)C#N Chemical compound C(C)[C@@H]1N(C[C@H](N(C1)[C@@H](CCC)C1=CC=C(C=C1)C(F)(F)F)CC)C=1C2=C(N(C(N=1)=O)C)C=CC(=N2)C#N RYANVYSVCYNQFK-VJBWXMMDSA-N 0.000 description 1
RYANVYSVCYNQFK-XPWALMASSA-N C(C)[C@@H]1N(C[C@H](N(C1)[C@H](CCC)C1=CC=C(C=C1)C(F)(F)F)CC)C=1C2=C(N(C(N=1)=O)C)C=CC(=N2)C#N Chemical compound C(C)[C@@H]1N(C[C@H](N(C1)[C@H](CCC)C1=CC=C(C=C1)C(F)(F)F)CC)C=1C2=C(N(C(N=1)=O)C)C=CC(=N2)C#N RYANVYSVCYNQFK-XPWALMASSA-N 0.000 description 1
BHXSVTMRKSKATQ-SCVGIUIWSA-N C(C)[C@H]1N(C[C@@H](N(C1)C=1C2=C(N(C(N=1)=O)C)C=CC(=N2)C#N)C)C(C)C1=CC=C(C=C1)OC(F)(F)F Chemical compound C(C)[C@H]1N(C[C@@H](N(C1)C=1C2=C(N(C(N=1)=O)C)C=CC(=N2)C#N)C)C(C)C1=CC=C(C=C1)OC(F)(F)F BHXSVTMRKSKATQ-SCVGIUIWSA-N 0.000 description 1
VXNPBWZDPVVFSO-ICTUGDKOSA-N C(C)[C@H]1N(C[C@@H](N(C1)C=1C2=C(N(C(N=1)=O)C)C=CC(=N2)C#N)C)C(CC)C1=CC=C(C=C1)C(F)(F)F Chemical compound C(C)[C@H]1N(C[C@@H](N(C1)C=1C2=C(N(C(N=1)=O)C)C=CC(=N2)C#N)C)C(CC)C1=CC=C(C=C1)C(F)(F)F VXNPBWZDPVVFSO-ICTUGDKOSA-N 0.000 description 1
HNRXYWATHQAJQJ-FZWXSHBKSA-N C(C)[C@H]1N(C[C@@H](N(C1)C=1C2=C(N(C(N=1)=O)C)C=CC(=N2)C#N)C)C(CC)C1=CC=C(C=C1)OC(F)(F)F Chemical compound C(C)[C@H]1N(C[C@@H](N(C1)C=1C2=C(N(C(N=1)=O)C)C=CC(=N2)C#N)C)C(CC)C1=CC=C(C=C1)OC(F)(F)F HNRXYWATHQAJQJ-FZWXSHBKSA-N 0.000 description 1
AIVDFWPDLDQNIT-TWOQFEAHSA-N C(C)[C@H]1N(C[C@@H](N(C1)C=1C2=C(N(C(N=1)=O)C)C=CC(=N2)C#N)C)[C@@H](C)C1=CC=C(C=C1)C(F)(F)F Chemical compound C(C)[C@H]1N(C[C@@H](N(C1)C=1C2=C(N(C(N=1)=O)C)C=CC(=N2)C#N)C)[C@@H](C)C1=CC=C(C=C1)C(F)(F)F AIVDFWPDLDQNIT-TWOQFEAHSA-N 0.000 description 1
BHXSVTMRKSKATQ-TXPKVOOTSA-N C(C)[C@H]1N(C[C@@H](N(C1)C=1C2=C(N(C(N=1)=O)C)C=CC(=N2)C#N)C)[C@@H](C)C1=CC=C(C=C1)OC(F)(F)F Chemical compound C(C)[C@H]1N(C[C@@H](N(C1)C=1C2=C(N(C(N=1)=O)C)C=CC(=N2)C#N)C)[C@@H](C)C1=CC=C(C=C1)OC(F)(F)F BHXSVTMRKSKATQ-TXPKVOOTSA-N 0.000 description 1
VXNPBWZDPVVFSO-DQLDELGASA-N C(C)[C@H]1N(C[C@@H](N(C1)C=1C2=C(N(C(N=1)=O)C)C=CC(=N2)C#N)C)[C@@H](CC)C1=CC=C(C=C1)C(F)(F)F Chemical compound C(C)[C@H]1N(C[C@@H](N(C1)C=1C2=C(N(C(N=1)=O)C)C=CC(=N2)C#N)C)[C@@H](CC)C1=CC=C(C=C1)C(F)(F)F VXNPBWZDPVVFSO-DQLDELGASA-N 0.000 description 1
HNRXYWATHQAJQJ-SCWSEQNSSA-N C(C)[C@H]1N(C[C@@H](N(C1)C=1C2=C(N(C(N=1)=O)C)C=CC(=N2)C#N)C)[C@@H](CC)C1=CC=C(C=C1)OC(F)(F)F Chemical compound C(C)[C@H]1N(C[C@@H](N(C1)C=1C2=C(N(C(N=1)=O)C)C=CC(=N2)C#N)C)[C@@H](CC)C1=CC=C(C=C1)OC(F)(F)F HNRXYWATHQAJQJ-SCWSEQNSSA-N 0.000 description 1
NALBGDIPGZZNPU-RRFXTLBOSA-N C(C)[C@H]1N(C[C@@H](N(C1)C=1C2=C(N(C(N=1)=O)C)C=CC(=N2)C#N)C)[C@H](C1=NC=C(C=C1)C(F)(F)F)C1=CC=C(C=C1)F Chemical compound C(C)[C@H]1N(C[C@@H](N(C1)C=1C2=C(N(C(N=1)=O)C)C=CC(=N2)C#N)C)[C@H](C1=NC=C(C=C1)C(F)(F)F)C1=CC=C(C=C1)F NALBGDIPGZZNPU-RRFXTLBOSA-N 0.000 description 1
QERRXAZVGOPRIH-SLSDLSHTSA-N C1(CC1)C1=NOC(=N1)[C@@H](N1C[C@@H](N(C[C@H]1CC)C=1C2=C(N(C(N=1)=O)C)C=CC(=N2)C#N)CC)C1=CC=C(C=C1)F Chemical compound C1(CC1)C1=NOC(=N1)[C@@H](N1C[C@@H](N(C[C@H]1CC)C=1C2=C(N(C(N=1)=O)C)C=CC(=N2)C#N)CC)C1=CC=C(C=C1)F QERRXAZVGOPRIH-SLSDLSHTSA-N 0.000 description 1
QERRXAZVGOPRIH-OTNCWRBYSA-N C1(CC1)C1=NOC(=N1)[C@H](N1C[C@@H](N(C[C@H]1CC)C=1C2=C(N(C(N=1)=O)C)C=CC(=N2)C#N)CC)C1=CC=C(C=C1)F Chemical compound C1(CC1)C1=NOC(=N1)[C@H](N1C[C@@H](N(C[C@H]1CC)C=1C2=C(N(C(N=1)=O)C)C=CC(=N2)C#N)CC)C1=CC=C(C=C1)F QERRXAZVGOPRIH-OTNCWRBYSA-N 0.000 description 1
BZTXHSBPBUQZBK-UFPGJGBJSA-N C1(CC1)COC1=CC(=C(C=C1)[C@H](CC)N1C[C@@H](N(C[C@H]1CC)C=1C2=C(N(C(N=1)=O)C)C=CC(=N2)C#N)CC)F Chemical compound C1(CC1)COC1=CC(=C(C=C1)[C@H](CC)N1C[C@@H](N(C[C@H]1CC)C=1C2=C(N(C(N=1)=O)C)C=CC(=N2)C#N)CC)F BZTXHSBPBUQZBK-UFPGJGBJSA-N 0.000 description 1
125000000882 C2-C6 alkenyl group Chemical group 0.000 description 1
125000003601 C2-C6 alkynyl group Chemical group 0.000 description 1
238000011740 C57BL/6 mouse Methods 0.000 description 1
KCBAMQOKOLXLOX-BSZYMOERSA-N CC1=C(SC=N1)C2=CC=C(C=C2)[C@H](C)NC(=O)[C@@H]3C[C@H](CN3C(=O)[C@H](C(C)(C)C)NC(=O)CCCCCCCCCCNCCCONC(=O)C4=C(C(=C(C=C4)F)F)NC5=C(C=C(C=C5)I)F)O Chemical compound CC1=C(SC=N1)C2=CC=C(C=C2)[C@H](C)NC(=O)[C@@H]3C[C@H](CN3C(=O)[C@H](C(C)(C)C)NC(=O)CCCCCCCCCCNCCCONC(=O)C4=C(C(=C(C=C4)F)F)NC5=C(C=C(C=C5)I)F)O KCBAMQOKOLXLOX-BSZYMOERSA-N 0.000 description 1
BQXUPNKLZNSUMC-YUQWMIPFSA-N CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 Chemical compound CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 BQXUPNKLZNSUMC-YUQWMIPFSA-N 0.000 description 1
MWXULEFQPDWBBB-XGHQBKJUSA-N CN1C(N=C(C2=C1C=CC(=N2)C#N)N1[C@H](CN([C@@H](C1)CCC)[C@@H](C)C1=CC=C(C=C1)C(F)(F)F)C)=O Chemical compound CN1C(N=C(C2=C1C=CC(=N2)C#N)N1[C@H](CN([C@@H](C1)CCC)[C@@H](C)C1=CC=C(C=C1)C(F)(F)F)C)=O MWXULEFQPDWBBB-XGHQBKJUSA-N 0.000 description 1
108091033409 CRISPR Proteins 0.000 description 1
238000010354 CRISPR gene editing Methods 0.000 description 1
HSUQIINJDORZRD-ZJUUUORDSA-N C[C@@H]1N(C[C@H](NC1)C)C=1C2=C(N(C(N=1)=O)C)C=CC(=N2)C#N Chemical compound C[C@@H]1N(C[C@H](NC1)C)C=1C2=C(N(C(N=1)=O)C)C=CC(=N2)C#N HSUQIINJDORZRD-ZJUUUORDSA-N 0.000 description 1
241000222120 Candida <Saccharomycetales> Species 0.000 description 1
206010007953 Central nervous system lymphoma Diseases 0.000 description 1
241000606161 Chlamydia Species 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
FZAWIXYDKIIODN-QCIUDXLNSA-N ClC1=CC=C(C=C1)[C@@H](N1C[C@@H](N(C[C@H]1CC)C=1C2=C(N(C(N=1)=O)C)C=CC(=N2)C#N)C)C1=NC=CC=C1 Chemical compound ClC1=CC=C(C=C1)[C@@H](N1C[C@@H](N(C[C@H]1CC)C=1C2=C(N(C(N=1)=O)C)C=CC(=N2)C#N)C)C1=NC=CC=C1 FZAWIXYDKIIODN-QCIUDXLNSA-N 0.000 description 1
FZAWIXYDKIIODN-MNDLBQGCSA-N ClC1=CC=C(C=C1)[C@H](N1C[C@@H](N(C[C@H]1CC)C=1C2=C(N(C(N=1)=O)C)C=CC(=N2)C#N)C)C1=NC=CC=C1 Chemical compound ClC1=CC=C(C=C1)[C@H](N1C[C@@H](N(C[C@H]1CC)C=1C2=C(N(C(N=1)=O)C)C=CC(=N2)C#N)C)C1=NC=CC=C1 FZAWIXYDKIIODN-MNDLBQGCSA-N 0.000 description 1
241000193155 Clostridium botulinum Species 0.000 description 1
241000223205 Coccidioides immitis Species 0.000 description 1
244000060011 Cocos nucifera Species 0.000 description 1
235000013162 Cocos nucifera Nutrition 0.000 description 1
229940126657 Compound 17 Drugs 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
241000711573 Coronaviridae Species 0.000 description 1
241000700626 Cowpox virus Species 0.000 description 1
241000709687 Coxsackievirus Species 0.000 description 1
229920002785 Croscarmellose sodium Polymers 0.000 description 1
201000007336 Cryptococcosis Diseases 0.000 description 1
241000221204 Cryptococcus neoformans Species 0.000 description 1
241000223935 Cryptosporidium Species 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
241000725619 Dengue virus Species 0.000 description 1
YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
101710192015 Diacylglycerol kinase zeta Proteins 0.000 description 1
102100030220 Diacylglycerol kinase zeta Human genes 0.000 description 1
BWLUMTFWVZZZND-UHFFFAOYSA-N Dibenzylamine Chemical compound C=1C=CC=CC=1CNCC1=CC=CC=C1 BWLUMTFWVZZZND-UHFFFAOYSA-N 0.000 description 1
XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 1
241001466953 Echovirus Species 0.000 description 1
208000001976 Endocrine Gland Neoplasms Diseases 0.000 description 1
241000224432 Entamoeba histolytica Species 0.000 description 1
241000709661 Enterovirus Species 0.000 description 1
241000991587 Enterovirus C Species 0.000 description 1
206010014950 Eosinophilia Diseases 0.000 description 1
208000031637 Erythroblastic Acute Leukemia Diseases 0.000 description 1
208000036566 Erythroleukaemia Diseases 0.000 description 1
101000867232 Escherichia coli Heat-stable enterotoxin II Proteins 0.000 description 1
239000001856 Ethyl cellulose Substances 0.000 description 1
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
208000001382 Experimental Melanoma Diseases 0.000 description 1
XNOWKAWYXXGCHS-YPBQGGFRSA-N FC1=CC=C(C=C1)[C@H](N1C[C@@H](N(C[C@H]1C)C=1C2=C(N(C(N=1)=O)C)C=CC(=N2)C#N)C)C1=NC=C(C=C1)C(F)(F)F Chemical compound FC1=CC=C(C=C1)[C@H](N1C[C@@H](N(C[C@H]1C)C=1C2=C(N(C(N=1)=O)C)C=CC(=N2)C#N)C)C1=NC=C(C=C1)C(F)(F)F XNOWKAWYXXGCHS-YPBQGGFRSA-N 0.000 description 1
201000001342 Fallopian tube cancer Diseases 0.000 description 1
208000013452 Fallopian tube neoplasm Diseases 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
229920001917 Ficoll Polymers 0.000 description 1
241000710831 Flavivirus Species 0.000 description 1
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical class OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
208000022072 Gallbladder Neoplasms Diseases 0.000 description 1
208000032612 Glial tumor Diseases 0.000 description 1
201000010915 Glioblastoma multiforme Diseases 0.000 description 1
206010018338 Glioma Diseases 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
108020005004 Guide RNA Proteins 0.000 description 1
102100036242 HLA class II histocompatibility antigen, DQ alpha 2 chain Human genes 0.000 description 1
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
241000228404 Histoplasma capsulatum Species 0.000 description 1
101100166600 Homo sapiens CD28 gene Proteins 0.000 description 1
101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 description 1
101000930801 Homo sapiens HLA class II histocompatibility antigen, DQ alpha 2 chain Proteins 0.000 description 1
101001042104 Homo sapiens Inducible T-cell costimulator Proteins 0.000 description 1
101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 1
206010062904 Hormone-refractory prostate cancer Diseases 0.000 description 1
108091006905 Human Serum Albumin Proteins 0.000 description 1
102000008100 Human Serum Albumin Human genes 0.000 description 1
241000598436 Human T-cell lymphotropic virus Species 0.000 description 1
241000700588 Human alphaherpesvirus 1 Species 0.000 description 1
241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
241000701806 Human papillomavirus Species 0.000 description 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
102000037982 Immune checkpoint proteins Human genes 0.000 description 1
108091008036 Immune checkpoint proteins Proteins 0.000 description 1
102000008070 Interferon-gamma Human genes 0.000 description 1
108010050904 Interferons Proteins 0.000 description 1
102000014150 Interferons Human genes 0.000 description 1
108090000978 Interleukin-4 Proteins 0.000 description 1
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical class CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
241000701460 JC polyomavirus Species 0.000 description 1
208000007766 Kaposi sarcoma Diseases 0.000 description 1
241000588748 Klebsiella Species 0.000 description 1
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
206010023791 Large granular lymphocytosis Diseases 0.000 description 1
208000032004 Large-Cell Anaplastic Lymphoma Diseases 0.000 description 1
241000589248 Legionella Species 0.000 description 1
208000007764 Legionnaires' Disease Diseases 0.000 description 1
241000589901 Leptospiraceae Species 0.000 description 1
206010024305 Leukaemia monocytic Diseases 0.000 description 1
108060001084 Luciferase Proteins 0.000 description 1
239000005089 Luciferase Substances 0.000 description 1
208000028018 Lymphocytic leukaemia Diseases 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
241000282567 Macaca fascicularis Species 0.000 description 1
206010025654 Malignant melanoma of sites other than skin Diseases 0.000 description 1
208000032271 Malignant tumor of penis Diseases 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
208000025205 Mantle-Cell Lymphoma Diseases 0.000 description 1
241000712079 Measles morbillivirus Species 0.000 description 1
206010027480 Metastatic malignant melanoma Diseases 0.000 description 1
241000700560 Molluscum contagiosum virus Species 0.000 description 1
241000235388 Mucorales Species 0.000 description 1
208000034578 Multiple myelomas Diseases 0.000 description 1
241000711386 Mumps virus Species 0.000 description 1
241000699660 Mus musculus Species 0.000 description 1
241000186359 Mycobacterium Species 0.000 description 1
208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
HTLZVHNRZJPSMI-UHFFFAOYSA-N N-ethylpiperidine Chemical compound CCN1CCCCC1 HTLZVHNRZJPSMI-UHFFFAOYSA-N 0.000 description 1
OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 1
229910002651 NO3 Inorganic materials 0.000 description 1
241000224438 Naegleria fowleri Species 0.000 description 1
241000588653 Neisseria Species 0.000 description 1
208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 description 1
206010029260 Neuroblastoma Diseases 0.000 description 1
PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
108091028043 Nucleic acid sequence Proteins 0.000 description 1
RCEAADKTGXTDOA-UHFFFAOYSA-N OS(O)(=O)=O.CCCCCCCCCCCC[Na] Chemical compound OS(O)(=O)=O.CCCCCCCCCCCC[Na] RCEAADKTGXTDOA-UHFFFAOYSA-N 0.000 description 1
108010075205 OVA-8 Proteins 0.000 description 1
240000007817 Olea europaea Species 0.000 description 1
235000007164 Oryza sativa Nutrition 0.000 description 1
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
241001631646 Papillomaviridae Species 0.000 description 1
208000000821 Parathyroid Neoplasms Diseases 0.000 description 1
229920002230 Pectic acid Polymers 0.000 description 1
208000002471 Penile Neoplasms Diseases 0.000 description 1
206010034299 Penile cancer Diseases 0.000 description 1
201000005746 Pituitary adenoma Diseases 0.000 description 1
201000007552 Pituitary carcinoma Diseases 0.000 description 1
206010061538 Pituitary tumour benign Diseases 0.000 description 1
208000007452 Plasmacytoma Diseases 0.000 description 1
241000223810 Plasmodium vivax Species 0.000 description 1
241000233872 Pneumocystis carinii Species 0.000 description 1
229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
229920001214 Polysorbate 60 Polymers 0.000 description 1
239000004372 Polyvinyl alcohol Substances 0.000 description 1
208000008691 Precursor B-Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
208000017414 Precursor T-cell acute lymphoblastic leukemia Diseases 0.000 description 1
OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
102000007327 Protamines Human genes 0.000 description 1
108010007568 Protamines Proteins 0.000 description 1
108010029485 Protein Isoforms Proteins 0.000 description 1
102000001708 Protein Isoforms Human genes 0.000 description 1
241000588769 Proteus <enterobacteria> Species 0.000 description 1
241000125945 Protoparvovirus Species 0.000 description 1
241000589516 Pseudomonas Species 0.000 description 1
241000589517 Pseudomonas aeruginosa Species 0.000 description 1
241000711798 Rabies lyssavirus Species 0.000 description 1
208000015634 Rectal Neoplasms Diseases 0.000 description 1
206010038111 Recurrent cancer Diseases 0.000 description 1
230000010757 Reduction Activity Effects 0.000 description 1
241000725643 Respiratory syncytial virus Species 0.000 description 1
241000235527 Rhizopus Species 0.000 description 1
241000606701 Rickettsia Species 0.000 description 1
241000702670 Rotavirus Species 0.000 description 1
241000710799 Rubella virus Species 0.000 description 1
208000004337 Salivary Gland Neoplasms Diseases 0.000 description 1
206010061934 Salivary gland cancer Diseases 0.000 description 1
241000607142 Salmonella Species 0.000 description 1
201000010208 Seminoma Diseases 0.000 description 1
239000012506 Sephacryl® Substances 0.000 description 1
241000607720 Serratia Species 0.000 description 1
244000000231 Sesamum indicum Species 0.000 description 1
235000003434 Sesamum indicum Nutrition 0.000 description 1
208000009359 Sezary Syndrome Diseases 0.000 description 1
208000000453 Skin Neoplasms Diseases 0.000 description 1
208000004346 Smoldering Multiple Myeloma Diseases 0.000 description 1
NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 1
241001149962 Sporothrix Species 0.000 description 1
208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 1
241000295644 Staphylococcaceae Species 0.000 description 1
241000191967 Staphylococcus aureus Species 0.000 description 1
239000012505 Superdex™ Substances 0.000 description 1
108091008874 T cell receptors Proteins 0.000 description 1
208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 1
208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 description 1
201000011648 T-cell childhood lymphoblastic lymphoma Diseases 0.000 description 1
208000037913 T-cell disorder Diseases 0.000 description 1
102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 1
PZBFGYYEXUXCOF-UHFFFAOYSA-N TCEP Chemical compound OC(=O)CCP(CCC(O)=O)CCC(O)=O PZBFGYYEXUXCOF-UHFFFAOYSA-N 0.000 description 1
206010043276 Teratoma Diseases 0.000 description 1
206010043376 Tetanus Diseases 0.000 description 1
241000223997 Toxoplasma gondii Species 0.000 description 1
YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
241000223105 Trypanosoma brucei Species 0.000 description 1
241000223109 Trypanosoma cruzi Species 0.000 description 1
208000023915 Ureteral Neoplasms Diseases 0.000 description 1
206010046392 Ureteric cancer Diseases 0.000 description 1
206010046431 Urethral cancer Diseases 0.000 description 1
206010046458 Urethral neoplasms Diseases 0.000 description 1
241000607626 Vibrio cholerae Species 0.000 description 1
208000033559 Waldenström macroglobulinemia Diseases 0.000 description 1
201000006083 Xeroderma Pigmentosum Diseases 0.000 description 1
241000607479 Yersinia pestis Species 0.000 description 1
JVVXZOOGOGPDRZ-SLFFLAALSA-N [(1R,4aS,10aR)-1,4a-dimethyl-7-propan-2-yl-2,3,4,9,10,10a-hexahydrophenanthren-1-yl]methanamine Chemical compound NC[C@]1(C)CCC[C@]2(C)C3=CC=C(C(C)C)C=C3CC[C@H]21 JVVXZOOGOGPDRZ-SLFFLAALSA-N 0.000 description 1
LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 description 1
LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 1
WERKSKAQRVDLDW-ANOHMWSOSA-N [(2s,3r,4r,5r)-2,3,4,5,6-pentahydroxyhexyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO WERKSKAQRVDLDW-ANOHMWSOSA-N 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
208000021841 acute erythroid leukemia Diseases 0.000 description 1
230000033289 adaptive immune response Effects 0.000 description 1
WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical class OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 1
201000005188 adrenal gland cancer Diseases 0.000 description 1
208000024447 adrenal gland neoplasm Diseases 0.000 description 1
201000006966 adult T-cell leukemia Diseases 0.000 description 1
208000037844 advanced solid tumor Diseases 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
229910052784 alkaline earth metal Inorganic materials 0.000 description 1
125000005907 alkyl ester group Chemical group 0.000 description 1
150000001350 alkyl halides Chemical class 0.000 description 1
125000002947 alkylene group Chemical group 0.000 description 1
229940087168 alpha tocopherol Drugs 0.000 description 1
AEMOLEFTQBMNLQ-BKBMJHBISA-N alpha-D-galacturonic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-BKBMJHBISA-N 0.000 description 1
HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
235000012211 aluminium silicate Nutrition 0.000 description 1
CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
229940063655 aluminum stearate Drugs 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
150000003863 ammonium salts Chemical class 0.000 description 1
230000003321 amplification Effects 0.000 description 1
206010002449 angioimmunoblastic T-cell lymphoma Diseases 0.000 description 1
238000005571 anion exchange chromatography Methods 0.000 description 1
230000001093 anti-cancer Effects 0.000 description 1
238000009175 antibody therapy Methods 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
230000007503 antigenic stimulation Effects 0.000 description 1
201000011165 anus cancer Diseases 0.000 description 1
239000008346 aqueous phase Substances 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
239000010425 asbestos Substances 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
125000003289 ascorbyl group Chemical class [H]O[C@@]([H])(C([H])([H])O*)[C@@]1([H])OC(=O)C(O*)=C1O* 0.000 description 1
239000000605 aspartame Substances 0.000 description 1
IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
235000010357 aspartame Nutrition 0.000 description 1
229960003438 aspartame Drugs 0.000 description 1
CKLJMWTZIZZHCS-REOHCLBHSA-L aspartate group Chemical class N[C@@H](CC(=O)[O-])C(=O)[O-] CKLJMWTZIZZHCS-REOHCLBHSA-L 0.000 description 1
XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 1
239000012298 atmosphere Substances 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
230000003190 augmentative effect Effects 0.000 description 1
244000052616 bacterial pathogen Species 0.000 description 1
208000007456 balantidiasis Diseases 0.000 description 1
229910052788 barium Inorganic materials 0.000 description 1
DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
239000011324 bead Substances 0.000 description 1
235000013871 bee wax Nutrition 0.000 description 1
239000012166 beeswax Substances 0.000 description 1
UPABQMWFWCMOFV-UHFFFAOYSA-N benethamine Chemical compound C=1C=CC=CC=1CNCCC1=CC=CC=C1 UPABQMWFWCMOFV-UHFFFAOYSA-N 0.000 description 1
JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
229940077388 benzenesulfonate Drugs 0.000 description 1
SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
150000001558 benzoic acid derivatives Chemical class 0.000 description 1
PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 1
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
102000015736 beta 2-Microglobulin Human genes 0.000 description 1
108010081355 beta 2-Microglobulin Proteins 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
XMIIGOLPHOKFCH-UHFFFAOYSA-N beta-phenylpropanoic acid Natural products OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
229960004853 betadex Drugs 0.000 description 1
208000026900 bile duct neoplasm Diseases 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
RGYZQSCFKFDECZ-UHFFFAOYSA-N bis(4-methylphenyl)methanol Chemical compound C1=CC(C)=CC=C1C(O)C1=CC=C(C)C=C1 RGYZQSCFKFDECZ-UHFFFAOYSA-N 0.000 description 1
201000000053 blastoma Diseases 0.000 description 1
210000000601 blood cell Anatomy 0.000 description 1
210000001772 blood platelet Anatomy 0.000 description 1
125000001246 bromo group Chemical group Br* 0.000 description 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
210000004899 c-terminal region Anatomy 0.000 description 1
FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
229910000024 caesium carbonate Inorganic materials 0.000 description 1
MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
150000001721 carbon Chemical group 0.000 description 1
125000002843 carboxylic acid group Chemical group 0.000 description 1
238000006555 catalytic reaction Methods 0.000 description 1
238000005277 cation exchange chromatography Methods 0.000 description 1
150000001768 cations Chemical class 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
230000005859 cell recognition Effects 0.000 description 1
229920006217 cellulose acetate butyrate Polymers 0.000 description 1
201000007455 central nervous system cancer Diseases 0.000 description 1
208000025997 central nervous system neoplasm Diseases 0.000 description 1
229940082500 cetostearyl alcohol Drugs 0.000 description 1
229960000541 cetyl alcohol Drugs 0.000 description 1
NVVXJVMOIGXUGC-UHFFFAOYSA-M chloropalladium(1+);dicyclohexyl-[2-[2,6-di(propan-2-yloxy)phenyl]phenyl]phosphane;2-phenylaniline Chemical compound [Pd+]Cl.NC1=CC=CC=C1C1=CC=CC=[C-]1.CC(C)OC1=CC=CC(OC(C)C)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 NVVXJVMOIGXUGC-UHFFFAOYSA-M 0.000 description 1
208000006990 cholangiocarcinoma Diseases 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
208000024207 chronic leukemia Diseases 0.000 description 1
208000009060 clear cell adenocarcinoma Diseases 0.000 description 1
238000003501 co-culture Methods 0.000 description 1
238000000576 coating method Methods 0.000 description 1
239000008119 colloidal silica Substances 0.000 description 1
210000001072 colon Anatomy 0.000 description 1
229940125797 compound 12 Drugs 0.000 description 1
229940126543 compound 14 Drugs 0.000 description 1
229940125810 compound 20 Drugs 0.000 description 1
229940126086 compound 21 Drugs 0.000 description 1
229940126208 compound 22 Drugs 0.000 description 1
229940125833 compound 23 Drugs 0.000 description 1
229940125961 compound 24 Drugs 0.000 description 1
229940125846 compound 25 Drugs 0.000 description 1
229940125851 compound 27 Drugs 0.000 description 1
229940127204 compound 29 Drugs 0.000 description 1
229940125877 compound 31 Drugs 0.000 description 1
238000009833 condensation Methods 0.000 description 1
230000005494 condensation Effects 0.000 description 1
238000013270 controlled release Methods 0.000 description 1
229940028617 conventional vaccine Drugs 0.000 description 1
239000002285 corn oil Substances 0.000 description 1
235000005687 corn oil Nutrition 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
229940099112 cornstarch Drugs 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
239000006184 cosolvent Substances 0.000 description 1
235000012343 cottonseed oil Nutrition 0.000 description 1
239000002385 cottonseed oil Substances 0.000 description 1
239000006071 cream Substances 0.000 description 1
229960001681 croscarmellose sodium Drugs 0.000 description 1
229960000913 crospovidone Drugs 0.000 description 1
235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
239000013078 crystal Substances 0.000 description 1
201000007241 cutaneous T cell lymphoma Diseases 0.000 description 1
208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
BALGDZWGNCXXES-UHFFFAOYSA-N cyclopentane;propanoic acid Chemical compound CCC(O)=O.C1CCCC1 BALGDZWGNCXXES-UHFFFAOYSA-N 0.000 description 1
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
230000003013 cytotoxicity Effects 0.000 description 1
231100000135 cytotoxicity Toxicity 0.000 description 1
GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
238000013461 design Methods 0.000 description 1
229910052805 deuterium Inorganic materials 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
150000008050 dialkyl sulfates Chemical class 0.000 description 1
206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
FSBVERYRVPGNGG-UHFFFAOYSA-N dimagnesium dioxido-bis[[oxido(oxo)silyl]oxy]silane hydrate Chemical compound O.[Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O FSBVERYRVPGNGG-UHFFFAOYSA-N 0.000 description 1
206010013023 diphtheria Diseases 0.000 description 1
ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
235000019797 dipotassium phosphate Nutrition 0.000 description 1
229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
238000011038 discontinuous diafiltration by volume reduction Methods 0.000 description 1
BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
238000010494 dissociation reaction Methods 0.000 description 1
230000005593 dissociations Effects 0.000 description 1
125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
229940043264 dodecyl sulfate Drugs 0.000 description 1
238000012377 drug delivery Methods 0.000 description 1
238000009510 drug design Methods 0.000 description 1
238000009509 drug development Methods 0.000 description 1
238000002296 dynamic light scattering Methods 0.000 description 1
239000003792 electrolyte Substances 0.000 description 1
239000003480 eluent Substances 0.000 description 1
239000012156 elution solvent Substances 0.000 description 1
201000008184 embryoma Diseases 0.000 description 1
239000003974 emollient agent Substances 0.000 description 1
230000001804 emulsifying effect Effects 0.000 description 1
239000008387 emulsifying waxe Substances 0.000 description 1
230000002357 endometrial effect Effects 0.000 description 1
229940007078 entamoeba histolytica Drugs 0.000 description 1
239000002702 enteric coating Substances 0.000 description 1
238000009505 enteric coating Methods 0.000 description 1
231100000655 enterotoxin Toxicity 0.000 description 1
230000007613 environmental effect Effects 0.000 description 1
230000004076 epigenetic alteration Effects 0.000 description 1
210000003743 erythrocyte Anatomy 0.000 description 1
CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
235000019325 ethyl cellulose Nutrition 0.000 description 1
229920001249 ethyl cellulose Polymers 0.000 description 1
239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
229940043351 ethyl-p-hydroxybenzoate Drugs 0.000 description 1
NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
239000000284 extract Substances 0.000 description 1
150000002191 fatty alcohols Chemical class 0.000 description 1
238000001914 filtration Methods 0.000 description 1
201000003444 follicular lymphoma Diseases 0.000 description 1
239000012737 fresh medium Substances 0.000 description 1
230000005714 functional activity Effects 0.000 description 1
244000053095 fungal pathogen Species 0.000 description 1
201000010175 gallbladder cancer Diseases 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
238000007429 general method Methods 0.000 description 1
230000004077 genetic alteration Effects 0.000 description 1
125000005456 glyceride group Chemical group 0.000 description 1
229940074045 glyceryl distearate Drugs 0.000 description 1
229940075507 glyceryl monostearate Drugs 0.000 description 1
229960002449 glycine Drugs 0.000 description 1
239000003979 granulating agent Substances 0.000 description 1
210000003714 granulocyte Anatomy 0.000 description 1
208000017750 granulocytic sarcoma Diseases 0.000 description 1
JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 1
229940093915 gynecological organic acid Drugs 0.000 description 1
150000004820 halides Chemical class 0.000 description 1
229910052736 halogen Inorganic materials 0.000 description 1
125000005843 halogen group Chemical group 0.000 description 1
150000002367 halogens Chemical class 0.000 description 1
239000007902 hard capsule Substances 0.000 description 1
238000003306 harvesting Methods 0.000 description 1
201000000459 head and neck squamous cell carcinoma Diseases 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
230000009033 hematopoietic malignancy Effects 0.000 description 1
229960002897 heparin Drugs 0.000 description 1
229920000669 heparin Polymers 0.000 description 1
206010066957 hepatosplenic T-cell lymphoma Diseases 0.000 description 1
MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
FBPFZTCFMRRESA-UHFFFAOYSA-N hexane-1,2,3,4,5,6-hexol Chemical compound OCC(O)C(O)C(O)C(O)CO FBPFZTCFMRRESA-UHFFFAOYSA-N 0.000 description 1
FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
210000003630 histaminocyte Anatomy 0.000 description 1
102000053578 human DGKZ Human genes 0.000 description 1
102000055277 human IL2 Human genes 0.000 description 1
210000005260 human cell Anatomy 0.000 description 1
229910000042 hydrogen bromide Inorganic materials 0.000 description 1
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
239000001863 hydroxypropyl cellulose Substances 0.000 description 1
230000036737 immune function Effects 0.000 description 1
229940045207 immuno-oncology agent Drugs 0.000 description 1
239000002955 immunomodulating agent Substances 0.000 description 1
239000003701 inert diluent Substances 0.000 description 1
206010022000 influenza Diseases 0.000 description 1
238000001802 infusion Methods 0.000 description 1
239000007972 injectable composition Substances 0.000 description 1
229940102223 injectable solution Drugs 0.000 description 1
229940102213 injectable suspension Drugs 0.000 description 1
229910001867 inorganic solvent Inorganic materials 0.000 description 1
239000003049 inorganic solvent Substances 0.000 description 1
229940079322 interferon Drugs 0.000 description 1
229960003130 interferon gamma Drugs 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
238000004255 ion exchange chromatography Methods 0.000 description 1
230000007794 irritation Effects 0.000 description 1
SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
238000011813 knockout mouse model Methods 0.000 description 1
239000010410 layer Substances 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
230000007774 longterm Effects 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
201000005249 lung adenocarcinoma Diseases 0.000 description 1
201000008443 lung non-squamous non-small cell carcinoma Diseases 0.000 description 1
201000005243 lung squamous cell carcinoma Diseases 0.000 description 1
210000004698 lymphocyte Anatomy 0.000 description 1
238000002794 lymphocyte assay Methods 0.000 description 1
230000000527 lymphocytic effect Effects 0.000 description 1
208000003747 lymphoid leukemia Diseases 0.000 description 1
210000003563 lymphoid tissue Anatomy 0.000 description 1
239000012139 lysis buffer Substances 0.000 description 1
201000000564 macroglobulinemia Diseases 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
239000000395 magnesium oxide Substances 0.000 description 1
CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
235000012245 magnesium oxide Nutrition 0.000 description 1
159000000003 magnesium salts Chemical class 0.000 description 1
239000000391 magnesium silicate Substances 0.000 description 1
229910052943 magnesium sulfate Inorganic materials 0.000 description 1
235000019341 magnesium sulphate Nutrition 0.000 description 1
229910000386 magnesium trisilicate Inorganic materials 0.000 description 1
229940099273 magnesium trisilicate Drugs 0.000 description 1
235000019793 magnesium trisilicate Nutrition 0.000 description 1
AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
201000004792 malaria Diseases 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
230000036210 malignancy Effects 0.000 description 1
230000003211 malignant effect Effects 0.000 description 1
208000029559 malignant endocrine neoplasm Diseases 0.000 description 1
208000020984 malignant renal pelvis neoplasm Diseases 0.000 description 1
201000000289 malignant teratoma Diseases 0.000 description 1
208000026045 malignant tumor of parathyroid gland Diseases 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
230000000873 masking effect Effects 0.000 description 1
230000013011 mating Effects 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
102000006240 membrane receptors Human genes 0.000 description 1
108020004084 membrane receptors Proteins 0.000 description 1
230000015654 memory Effects 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
230000001394 metastastic effect Effects 0.000 description 1
208000037819 metastatic cancer Diseases 0.000 description 1
208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
208000021039 metastatic melanoma Diseases 0.000 description 1
206010061289 metastatic neoplasm Diseases 0.000 description 1
AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical class CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
229940098779 methanesulfonic acid Drugs 0.000 description 1
GUWDPMLFISTXNO-UHFFFAOYSA-N methyl 1-[bis(4-fluorophenyl)methyl]piperazine-2-carboxylate Chemical compound FC1=CC=C(C=C1)C(N1C(CNCC1)C(=O)OC)C1=CC=C(C=C1)F GUWDPMLFISTXNO-UHFFFAOYSA-N 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
235000010446 mineral oil Nutrition 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
210000001616 monocyte Anatomy 0.000 description 1
201000006894 monocytic leukemia Diseases 0.000 description 1
210000004877 mucosa Anatomy 0.000 description 1
230000035772 mutation Effects 0.000 description 1
229940043348 myristyl alcohol Drugs 0.000 description 1
125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
HEGSGKPQLMEBJL-UHFFFAOYSA-N n-octyl beta-D-glucopyranoside Natural products CCCCCCCCOC1OC(CO)C(O)C(O)C1O HEGSGKPQLMEBJL-UHFFFAOYSA-N 0.000 description 1
125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
229910052759 nickel Inorganic materials 0.000 description 1
235000001968 nicotinic acid Nutrition 0.000 description 1
239000011664 nicotinic acid Substances 0.000 description 1
150000002823 nitrates Chemical class 0.000 description 1
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
238000003199 nucleic acid amplification method Methods 0.000 description 1
239000007764 o/w emulsion Substances 0.000 description 1
GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 1
239000003883 ointment base Substances 0.000 description 1
239000006186 oral dosage form Substances 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
201000008968 osteosarcoma Diseases 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
125000004430 oxygen atom Chemical group O* 0.000 description 1
KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 1
239000012188 paraffin wax Substances 0.000 description 1
244000045947 parasite Species 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
235000020232 peanut Nutrition 0.000 description 1
125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
239000002304 perfume Substances 0.000 description 1
210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
201000005528 peripheral nervous system neoplasm Diseases 0.000 description 1
201000002628 peritoneum cancer Diseases 0.000 description 1
JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical compound [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
RLOWWWKZYUNIDI-UHFFFAOYSA-N phosphinic chloride Chemical compound ClP=O RLOWWWKZYUNIDI-UHFFFAOYSA-N 0.000 description 1
229940075930 picrate Drugs 0.000 description 1
OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 1
239000006187 pill Substances 0.000 description 1
208000011866 pituitary adenocarcinoma Diseases 0.000 description 1
208000021310 pituitary gland adenoma Diseases 0.000 description 1
229950010765 pivalate Drugs 0.000 description 1
IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
229920000058 polyacrylate Polymers 0.000 description 1
229920000515 polycarbonate Polymers 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
229940113116 polyethylene glycol 1000 Drugs 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
229920000136 polysorbate Polymers 0.000 description 1
229920002451 polyvinyl alcohol Polymers 0.000 description 1
235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
208000017805 post-transplant lymphoproliferative disease Diseases 0.000 description 1
IUBQJLUDMLPAGT-UHFFFAOYSA-N potassium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([K])[Si](C)(C)C IUBQJLUDMLPAGT-UHFFFAOYSA-N 0.000 description 1
159000000001 potassium salts Chemical class 0.000 description 1
239000004302 potassium sorbate Substances 0.000 description 1
235000010241 potassium sorbate Nutrition 0.000 description 1
229940069338 potassium sorbate Drugs 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
230000002265 prevention Effects 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
208000016800 primary central nervous system lymphoma Diseases 0.000 description 1
208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
201000006037 primary mediastinal B-cell lymphoma Diseases 0.000 description 1
MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
229960004919 procaine Drugs 0.000 description 1
238000012545 processing Methods 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
235000013772 propylene glycol Nutrition 0.000 description 1
229950008679 protamine sulfate Drugs 0.000 description 1
238000010926 purge Methods 0.000 description 1
ZIEWSZYVEDTXGH-UHFFFAOYSA-N pyrimidine-4-carbonitrile Chemical compound N#CC1=CC=NC=N1 ZIEWSZYVEDTXGH-UHFFFAOYSA-N 0.000 description 1
230000035484 reaction time Effects 0.000 description 1
206010038038 rectal cancer Diseases 0.000 description 1
201000001275 rectum cancer Diseases 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
208000015347 renal cell adenocarcinoma Diseases 0.000 description 1
201000007444 renal pelvis carcinoma Diseases 0.000 description 1
238000011160 research Methods 0.000 description 1
239000011347 resin Substances 0.000 description 1
229920005989 resin Polymers 0.000 description 1
235000009566 rice Nutrition 0.000 description 1
229910052895 riebeckite Inorganic materials 0.000 description 1
CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
235000019204 saccharin Nutrition 0.000 description 1
229940081974 saccharin Drugs 0.000 description 1
239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
229960001860 salicylate Drugs 0.000 description 1
238000013341 scale-up Methods 0.000 description 1
HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
239000013049 sediment Substances 0.000 description 1
210000001741 seminiferous epithelium Anatomy 0.000 description 1
238000013207 serial dilution Methods 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
238000010898 silica gel chromatography Methods 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
229940121497 sintilimab Drugs 0.000 description 1
238000001542 size-exclusion chromatography Methods 0.000 description 1
201000000849 skin cancer Diseases 0.000 description 1
201000002314 small intestine cancer Diseases 0.000 description 1
201000009295 smoldering myeloma Diseases 0.000 description 1
AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
229910001467 sodium calcium phosphate Inorganic materials 0.000 description 1
229910000029 sodium carbonate Inorganic materials 0.000 description 1
BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
239000001488 sodium phosphate Substances 0.000 description 1
159000000000 sodium salts Chemical class 0.000 description 1
239000007901 soft capsule Substances 0.000 description 1
238000007614 solvation Methods 0.000 description 1
239000004334 sorbic acid Substances 0.000 description 1
235000010199 sorbic acid Nutrition 0.000 description 1
229940075582 sorbic acid Drugs 0.000 description 1
229940083466 soybean lecithin Drugs 0.000 description 1
239000003549 soybean oil Substances 0.000 description 1
235000012424 soybean oil Nutrition 0.000 description 1
229950007213 spartalizumab Drugs 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
238000010186 staining Methods 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000007858 starting material Substances 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
238000004659 sterilization and disinfection Methods 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
229960004793 sucrose Drugs 0.000 description 1
BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
230000008093 supporting effect Effects 0.000 description 1
238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
150000003892 tartrate salts Chemical class 0.000 description 1
LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
150000003536 tetrazoles Chemical group 0.000 description 1
239000002562 thickening agent Substances 0.000 description 1
239000010409 thin film Substances 0.000 description 1
150000003567 thiocyanates Chemical class 0.000 description 1
229950007123 tislelizumab Drugs 0.000 description 1
239000003104 tissue culture media Substances 0.000 description 1
LBLYYCQCTBFVLH-UHFFFAOYSA-M toluenesulfonate group Chemical group C=1(C(=CC=CC1)S(=O)(=O)[O-])C LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 1
125000005490 tosylate group Chemical group 0.000 description 1
238000001890 transfection Methods 0.000 description 1
230000009466 transformation Effects 0.000 description 1
238000000844 transformation Methods 0.000 description 1
238000011830 transgenic mouse model Methods 0.000 description 1
238000011269 treatment regimen Methods 0.000 description 1
125000005270 trialkylamine group Chemical group 0.000 description 1
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
229910052722 tritium Inorganic materials 0.000 description 1
230000005747 tumor angiogenesis Effects 0.000 description 1
210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 1
ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical class CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 1
241000701161 unidentified adenovirus Species 0.000 description 1
241001529453 unidentified herpesvirus Species 0.000 description 1
241000712461 unidentified influenza virus Species 0.000 description 1
201000011294 ureter cancer Diseases 0.000 description 1
206010046885 vaginal cancer Diseases 0.000 description 1
208000013139 vaginal neoplasm Diseases 0.000 description 1
235000013311 vegetables Nutrition 0.000 description 1
229940118696 vibrio cholerae Drugs 0.000 description 1
125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
239000011345 viscous material Substances 0.000 description 1
239000003039 volatile agent Substances 0.000 description 1
210000002268 wool Anatomy 0.000 description 1
238000010626 work up procedure Methods 0.000 description 1
229940055760 yervoy Drugs 0.000 description 1
150000003751 zinc Chemical class 0.000 description 1

Images

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2815—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD8
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
- C07K16/3084—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

JP2022537676A 2019-12-19 2020-12-18 Ｄｇｋ阻害剤およびチェックポイントアンタゴニストの組み合わせ Pending JP2023510108A (ja)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201962950570P	2019-12-19	2019-12-19
US62/950,570		2019-12-19
PCT/US2020/066198 WO2021127554A1 (fr)	2019-12-19	2020-12-18	Combinaisons d'inhibiteurs de dgk et d'antagonistes de points de contrôle

Publications (2)

Publication Number	Publication Date
JP2023510108A true JP2023510108A (ja)	2023-03-13
JPWO2021127554A5 JPWO2021127554A5 (fr)	2023-12-25

Family

ID=74195132

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2022537676A Pending JP2023510108A (ja)	2019-12-19	2020-12-18	Ｄｇｋ阻害剤およびチェックポイントアンタゴニストの組み合わせ

Country Status (11)

Country	Link
US (1)	US20230089255A1 (fr)
EP (1)	EP4076529A1 (fr)
JP (1)	JP2023510108A (fr)
KR (1)	KR20220118481A (fr)
CN (1)	CN115243721A (fr)
AU (1)	AU2020407130A1 (fr)
BR (1)	BR112022009631A2 (fr)
CA (1)	CA3158532A1 (fr)
IL (1)	IL294085A (fr)
MX (1)	MX2022006932A (fr)
WO (1)	WO2021127554A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA3165735A1 (fr)	2019-12-24	2021-07-01	Carna Biosciences, Inc.	Composes modulant la diacylglycerol kinase
CN111097048A (zh) *	2019-12-27	2020-05-05	中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所）	Dgka抑制剂在制备用于促进抗肿瘤免疫治疗功效的药物中的应用
US11926628B2 (en)	2021-06-23	2024-03-12	Gilead Sciences, Inc.	Diacylglyercol kinase modulating compounds
US11976072B2 (en)	2021-06-23	2024-05-07	Gilead Sciences, Inc.	Diacylglycerol kinase modulating compounds
CA3220923A1 (fr)	2021-06-23	2022-12-29	Gilead Sciences, Inc.	Composes de modulation de la diacylglycerol kinase

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5851795A (en)	1991-06-27	1998-12-22	Bristol-Myers Squibb Company	Soluble CTLA4 molecules and uses thereof
US6051227A (en)	1995-07-25	2000-04-18	The Regents Of The University Of California, Office Of Technology Transfer	Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
ES2340745T3 (es)	1998-12-23	2010-06-08	Pfizer Inc.	Anticuerpos monoclonales humanos contra ctla-4.
EE05627B1 (et)	1998-12-23	2013-02-15	Pfizer Inc.	CTLA-4 vastased inimese monoklonaalsed antikehad
PT1210428E (pt)	1999-08-23	2015-07-21	Genetics Inst Llc	Pd-1, um recetor para b7-4 e suas utilizações
EP1212422B1 (fr)	1999-08-24	2007-02-21	Medarex, Inc.	Anticorps contre l'antigene ctla-4 humain et utilisation
JP2003520828A (ja)	2000-01-27	2003-07-08	ジェネティクスインスティテュート，エルエルシー	Ｃｔｌａ４（ｃｄ１５２）に対する抗体、これを含む結合体、およびその使用
CN101899114A (zh)	2002-12-23	2010-12-01	惠氏公司	抗pd-1抗体及其用途
US7381401B2 (en) *	2004-01-08	2008-06-03	The University Of Chicago	T cell anergy is reversed by active Ras and regulated by diacylglycerol kinase
CA2970873C (fr)	2005-05-09	2022-05-17	E. R. Squibb & Sons, L.L.C.	Anticorps monoclonaux humains pour mort programmee 1 (mp-1) et procedes pour traiter le cancer en utilisant des anticorps anti-mp-1 seuls ou associes a d'autres immunotherapies
CN104356236B (zh)	2005-07-01	2020-07-03	E.R.施贵宝&圣斯有限责任公司	抗程序性死亡配体1(pd-l1)的人单克隆抗体
CA2647282A1 (fr)	2006-04-05	2007-10-11	Pfizer Products Inc.	Polytherapie a base d'un anticorps anti-ctla4
EP3222634A1 (fr)	2007-06-18	2017-09-27	Merck Sharp & Dohme B.V.	Anticorps dirigés contre le récepteur humain de mort programmée pd-1
EP2262837A4 (fr)	2008-03-12	2011-04-06	Merck Sharp & Dohme	Protéines de liaison avec pd-1
PE20120341A1 (es)	2008-12-09	2012-04-24	Genentech Inc	Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t
KR101573109B1 (ko)	2009-11-24	2015-12-01	메디뮨 리미티드	Ｂ７―ｈ１에 대한 표적화된 결합 물질
EP2710137B1 (fr)	2011-03-10	2018-09-19	Provectus Pharmatech, Inc.	Une combinaison de rose bengale et un antikorps anti-ctla4 pour le traitement du cancer
CA2833636A1 (fr)	2011-04-20	2012-10-26	Amplimmune, Inc.	Anticorps et autres molecules qui se lient a b7-h1 et a pd-1
LT2785375T (lt)	2011-11-28	2020-11-10	Merck Patent Gmbh	Anti-pd-l1 antikūnai ir jų panaudojimas
US9856320B2 (en)	2012-05-15	2018-01-02	Bristol-Myers Squibb Company	Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
CN115093480A (zh)	2012-05-31	2022-09-23	索伦托药业有限公司	与pd-l1结合的抗原结合蛋白
EP3508215A3 (fr)	2012-12-03	2019-10-02	Bristol-Myers Squibb Company	Amélioration de l'activité anticancéreuse de protéines de fusion fc immunomodulatrices
EP2992017B1 (fr)	2013-05-02	2020-11-18	AnaptysBio, Inc.	Anticorps dirigés contre la protéine de mort programmée 1 (pd-1)
JP6563906B2 (ja)	2013-05-31	2019-08-21	ソレント・セラピューティクス・インコーポレイテッドＳｏｒｒｅｎｔｏＴｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ．	Ｐｄ−１に結合する抗原結合蛋白質
CN104250302B (zh)	2013-06-26	2017-11-14	上海君实生物医药科技股份有限公司	抗pd‑1抗体及其应用
AU2013400609B9 (en)	2013-09-13	2020-03-05	Beigene Switzerland Gmbh	Anti-PD1 antibodies and their use as therapeutics and diagnostics
CR20160319A (es)	2013-12-12	2016-11-08	Jiangsu Hengrui Medicine Co	Anticuerpo pd-1, fragmento de union al antigeno de este y uso médico de este
TWI681969B (zh)	2014-01-23	2020-01-11	美商再生元醫藥公司	針對ｐｄ-１的人類抗體
JOP20200094A1 (ar)	2014-01-24	2017-06-16	Dana Farber Cancer Inst Inc	جزيئات جسم مضاد لـ pd-1 واستخداماتها
EP3916017A1 (fr)	2014-12-22	2021-12-01	PD-1 Acquisition Group, LLC	Anticorps anti-pd-1
CA2978942A1 (fr)	2015-03-13	2016-09-22	Cytomx Therapeutics, Inc.	Anticorps anti-pdl1, anticorps anti-pld1 activables, et leurs procedes d'utilisation
DK3303394T3 (da)	2015-05-29	2020-07-06	Agenus Inc	Anti-ctla-4-antistoffer og fremgangsmåder til anvendelse deraf
WO2016197367A1 (fr)	2015-06-11	2016-12-15	Wuxi Biologics (Shanghai) Co. Ltd.	Nouveaux anticorps anti-pd-l1
PT3328419T (pt)	2015-07-30	2021-11-26	Macrogenics Inc	Moléculas de ligação pd-1 e métodos de utilização
WO2017020291A1 (fr)	2015-08-06	2017-02-09	Wuxi Biologics (Shanghai) Co. Ltd.	Nouveaux anticorps anti-pd-l1
WO2017024465A1 (fr)	2015-08-10	2017-02-16	Innovent Biologics (Suzhou) Co., Ltd.	Anticorps anti-pd-1
WO2017024515A1 (fr)	2015-08-11	2017-02-16	Wuxi Biologics (Cayman) Inc.	Nouveaux anticorps anti-pd-1
SG10201914109VA (en)	2015-08-11	2020-02-27	Wuxi Biologics Cayman Inc	Novel anti-pd-1 antibodies
AR105654A1 (es)	2015-08-24	2017-10-25	Lilly Co Eli	Anticuerpos pd-l1 (ligando 1 de muerte celular programada)
MA48579A (fr)	2015-09-01	2020-03-18	Agenus Inc	Anticorps anti-pd1 et méthodes d'utilisation de ceux-ci
SG11201804839WA (en)	2015-12-14	2018-07-30	Macrogenics Inc	Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof
CN108697776A (zh)	2016-01-11	2018-10-23	阿尔莫生物科技股份有限公司	在产生抗原特异性cd8+t细胞中的白介素-10及其使用方法
CN111491362B (zh)	2016-02-02	2023-10-24	华为技术有限公司	确定发射功率的方法、用户设备和基站
WO2017132827A1 (fr)	2016-02-02	2017-08-10	Innovent Biologics (Suzhou) Co., Ltd.	Anticorps anti-pd-1
BR112019008223A2 (pt)	2016-11-03	2019-07-16	Bristol-Myers Squibb Company	anticorpos anti-ctla-4 ativáveis e usos dos mesmos
AU2019262589B2 (en) *	2018-05-04	2022-07-07	Amgen Inc.	KRAS G12C inhibitors and methods of using the same
WO2020006018A1 (fr) *	2018-06-27	2020-01-02	Bristol-Myers Squibb Company	Composés de naphtyridinone substitués utiles en tant qu'activateurs de lymphocytes t
CA3104647A1 (fr) *	2018-06-27	2020-01-02	Bristol-Myers Squibb Company	Composes de naphtyridinone utiles en tant qu'activateurs de lymphocytes t
AR119821A1 (es) *	2019-08-28	2022-01-12	Bristol Myers Squibb Co	Compuestos de piridopirimidinonilo sustituidos útiles como activadores de células t

2020
- 2020-12-18 CN CN202080088924.5A patent/CN115243721A/zh active Pending
- 2020-12-18 AU AU2020407130A patent/AU2020407130A1/en active Pending
- 2020-12-18 IL IL294085A patent/IL294085A/en unknown
- 2020-12-18 WO PCT/US2020/066198 patent/WO2021127554A1/fr unknown
- 2020-12-18 CA CA3158532A patent/CA3158532A1/fr active Pending
- 2020-12-18 US US17/786,442 patent/US20230089255A1/en active Pending
- 2020-12-18 MX MX2022006932A patent/MX2022006932A/es unknown
- 2020-12-18 KR KR1020227024305A patent/KR20220118481A/ko unknown
- 2020-12-18 EP EP20845282.1A patent/EP4076529A1/fr active Pending
- 2020-12-18 JP JP2022537676A patent/JP2023510108A/ja active Pending
- 2020-12-18 BR BR112022009631A patent/BR112022009631A2/pt unknown

Also Published As

Publication number	Publication date
CA3158532A1 (fr)	2021-06-24
BR112022009631A2 (pt)	2022-08-09
CN115243721A (zh)	2022-10-25
MX2022006932A (es)	2022-07-11
AU2020407130A1 (en)	2022-06-16
EP4076529A1 (fr)	2022-10-26
IL294085A (en)	2022-08-01
US20230089255A1 (en)	2023-03-23
KR20220118481A (ko)	2022-08-25
WO2021127554A1 (fr)	2021-06-24

Legal Events

Date

Code

Title

Description

2023-12-15

A521

Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231215